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MicroRNAs (miRNAs) are short non-coding RNA molecules of ~22 nt in length that 
function as regulators of gene expression. They bind to the 3’ UTR of target mRNAs 
in a non-perfect complimentary manner, leading to either their degradation or 
translational repression. Over half of all protein coding genes contain miRNA target 
sites, meaning that miRNAs are involved in the regulation of virtually every cellular 
pathway. Because of this, miRNAs themselves are under strict regulation, often 
expressed in temporal or tissue-specific manners.  
MiRNAs are transcribed as long primary transcripts (pri-miRs) with stem-loop 
structures that are processed in the nucleus into ~70nt hairpins (pre-miRs), exported 
into the cytoplasm and cleaved into miRNA duplexes. MiRNA duplexes are 
incorporated into Ago proteins which retain single stranded mature miRNA in a 
functional RISC complex. Regulation of miRNA biogenesis occurs both at a 
transcriptional and post-transcriptional level. Various proteins that function in the 
post-transcriptional regulation of miRNA biogenesis have been described. However, 
in recent years, proteome-wide studies have expanded our knowledge of RNA-
binding proteins (RBPs). Many non-canonical RBPs with unknown roles in RNA 
metabolism have been identified. This expanded repertoire of RBP represents a new 
pool of potential miRNA biogenesis regulators. One group of interest amongst newly 
identified non-canonical RBPs are metabolic enzymes which are beginning to show a 
role in RNA metabolism, providing a link between gene regulation and cellular 
metabolism that is not yet fully understood. 
This study has focused on better understanding the post-transcriptional regulation of 
miRNA biogenesis in several systems. Firstly, protein factors involved in the 
regulation of miRNA cluster 14q32 were sought. This cluster represents the largest 
mammalian miRNA cluster and is important in mediating the response to ischemia. 
In this study, two proteins, cold-induced RNA binding protein (CIRBP) and 
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta 
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(HADHB), were identified as post-transcriptional regulators of selected 14q32 
miRNAs and further validated in cellular systems. 
Next, the mechanism underlying the control of miRNA biogenesis by known RBP 
regulator, cell lineage abnormal 28a (Lin28a), was explored in further detail. Lin28a 
represents the best-studied example of post-transcriptional miRNA regulation, 
influencing both nuclear and cytoplasmic let-7 processing as well as mediating pre-
let-7 uridylation and subsequent degradation. Lin28a can also regulate neuro-specific 
miR-9 which differs in sequence and structure from let-7. Here we showed that both 
miRNA precursors interact with different domains of Lin28a and the mechanisms 
regulation are different. This shows how a single RBP can have extensive effects in 
the regulation of miRNA biogenesis in different cellular contexts. 
Finally, in this study the inhibition by oleic acid (OA) of HuR and MSI2 binding to 
pri-miR-7 was explored. MSI2 in a complex with HuR inhibits biogenesis of neuro-
enriched miR-7. OA is the most abundant fatty acid and had previously been shown 
to inhibit the RNA-binding of MSI2 homolog, MSI1. Here this knowledge was 
extended to show that OA also inhibits MSI2 and HuR binding to pri-miR-7, increasing 
its processing. This gives an example of a mechanism regulating the interaction of 
miRNA precursors with regulatory proteins, modulating the effect of these proteins 
on miRNA biogenesis.  This also provided additional links between metabolism and 
regulation of RNA processing. 
In general, these investigations add to the current knowledge on post-transcriptional 
regulation of miRNAs and highlight the complexity of this system. Different 
mechanisms governing regulation of miRNA processing coexists in cells. Therefore, 
better understanding the individual factors at play will allow to generate a better 






Every cell in our body contains an identical copy of DNA, however these cells have to 
carry out different functions depending on their stage of development, the organ 
they belong to or the environmental stress they are subjected to. To achieve this, our 
cells employ various mechanisms to control which genes (or bits of DNA) are actively 
being used. One of these mechanisms involves the use of special regulatory 
molecules named microRNAs (or miRNAs for short).  
Our DNA is made up of four different bases; these bases serve as a four-letter code 
that our cells are able to interpret in order to make useful molecules named proteins 
out of our genes. In order to carry out this process, cells create a copy of our DNA 
which is known as RNA. The RNA copy of a gene is known as messenger RNA and it 
has the same sequence of bases as DNA; but unlike DNA each cell can have multiple 
RNA copies of a single gene, meaning more of that type of protein will be produced. 
Like messenger RNA, miRNAs are made up of RNA, but they do not code for proteins. 
Instead miRNAs can bind to messenger RNAs with similar sequences to them and 
destroy them. This is very important for our cells as it ensures that only the necessary 
proteins for each cell-type and developmental stage are produced and the levels of 
these can be fine-tuned according to the needs of the cell. Because of this, expression 
of miRNAs in incorrect temporal and spatial patterns can lead to many diseases 
including cardiovascular diseases, neurodegenerative diseases and cancer. 
The focus of this thesis has been to understand how cells control which miRNAs are 
produced. I have looked at the regulatory mechanisms behind the expression of 
miRNAs in three different scenarios. Firstly, I looked at a group of miRNAs whose 
levels increase when there is a lack of blood flow to the tissue and have identified 
two new proteins involved in regulation of miRNA. Secondly, I explored the roles of a 
known protein called Lin28a in controlling the levels of different miRNAs during the 
development of the brain. Finally, I looked at how fatty acids, which are common 
x 
 
components of our cells and our diets can affect the proteins that bind to and control 
the production of miRNAs. 
Because miRNAs are found dysregulated in a variety of diseases,  identifying the  
regulators of miRNA biogenesis provides potential targets for the future 





AD   Alzheimer’s disease 
ADAR   adenosine deaminases acting on RNA 
AGO   argonaute 
ARE AU-rich element 
ATP   adenosine triphosphate  
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MiRNA Biogenesis, functions and genomic organization 
 
MicroRNAs (miRNAs) are short non-coding RNAs  ~22 nt in length that function as 
important regulators of gene expression1. They constitute one of three classes of 
small silencing RNAs found in animals along with short interfering RNAs (siRNAs) and 
piwi interacting RNAs (piRNAs) each distinguished by their biogenetic pathway and 
associated effector proteins2. MiRNAs carry out their function within a RNA induced 
silencing complex (RISC)3 where they serve as guides directing the RISC towards 
target messenger RNAs (mRNAs) by binding to partially complementary sequences in 
their 3’UTR regions. In turn, binding of the RISC leads to either degradation or 
translational repression of the mRNAs4,5.  
The first miRNA, lin-4, was identified as a regulator of protein Lin-14 in the 
developmental stages of C. elegans in 19936,7. For several years this was believed to 
be the sole example of a rare phenomenon, exclusive to nematodes. However in 2000 
a second miRNA, let-7, was described and importantly, found to be conserved across 
the animal kingdom8,9. Studies quickly followed showing that these two molecules 
where in fact members of a much larger family of RNAs, containing hundreds of highly 
conserved members and representing a common regulatory mechanism10–12. 
Currently, there are 2654 human and 1978 murine mature miRNAs annotated in the 
online database miRBase13. These regulate the expression of a large number of 
protein coding and non-coding genes, with approximately 60% of mRNAs predicted 
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to contain miRNA target sites14. MiRNAs have been found to be involved in virtually 
every cellular process and are essential in development, differentiation and 
homeostasis1,2,15. A majority of miRNAs are expressed in tissue-specific and temporal 
specific patterns16  and many diseases are associated with their disregulation 
including cancer, neurodegenerative diseases, metabolic diseases and cardiovascular 
diseases17–21. Their importance is further highlighted by murine loss-of-function 
studies, in which disruption of miRNA genes produces mouse phenotypes with 
various developmental, cellular, physiological and behavioural defects which affect 
viability and can lead to the development of severe health conditions15. Furthermore, 






MiRNA biogenesis pathway 
Canonical MiRNA biogenesis 
Canonical miRNA biogenesis requires two sequential cleavages mediated by RNase III 
type endonucleases DROSHA and DICER24,25 (Figure 1). RNAse III endonucleases show 
specificity for double stranded RNA and generate characteristic products with 5′ 
monophosphate groups and two-nucleotide 3′ overhangs26, which are important for 
recognition by the miRNA biogenesis machinery27. MiRNAs are first transcribed as 
long primary transcripts (pri-miRs) which are variable in length and can often contain 
multiple mature miRNAs which are found clustered in the genome and transcribed 
as a single polycistronic unit24. Pri-miRs can either be transcribed from independent 
promoters, or can be found within transcripts of both protein-coding and non-coding 
sequences2. Most pri-miRs are transcribed by RNA Polymerase II (Pol II)28,29, however 
viral miRNAs processed through atypical mechanisms have been shown to be 
transcribed by RNA Polymerase III (Pol III)30,31.  
Embedded in pri-miRs are RNA stem-loop structures that are recognized and cleaved 
by DROSHA in the nucleus25. In order to function DROSHA requires interaction with a 
second protein; DGCR8 (DiGeorge syndrome chromosomal region 8). These proteins 
form the core of a heterotrimeric complex known as the microprocessor, composed 
of two DGCR8 units and one DROSHA subunit and which can also include various co-
factors27,32–36. Aside from its established role in miRNA biogenesis, the 
microprocessor can also bind and regulate a variety of cellular RNAs including mRNAs, 
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long non-coding RNAs and RNAs derived from retrotransposons37–40. Additionally, 
DGCR8 is able to associate with other nucleases and as such is able to mediate small 
nucleolar RNA (snoRNA)- cleavage in a DROSHA-independent manner41. 
Within the microprocessor, DROSHA cleaves the pri-miR contained RNA stem loops 
~11bp from the base of the stem and in doing so determines the final mature miRNA 
sequences as this cleavage also fixes the site for the subsequent cleavage by DICER42. 
Several structure and sequence features of pri-miRs distinguish them from other 
hairpin containing transcripts and enhance their recognition and processing by the 
microprocessor. Structurally, pri-miRs are comprised of a ~35 bp imperfect stem 
structure with an apical loop and unpaired segments at the base42,43. Additionally, 
various sequence features positively influence microprocessor recognition including 
a mismatched ‘GHG’ motif positioned mid-stem, a basal ‘UG’, an apical ‘UGUG’ and a 
‘CNNC’ motif ~17 nt downstream of the DROSHA cleavage site43,44. This first cleavage 
step frequently occurs co-transcriptionally and co-ordinately with splicing45–47. 
The stem-loop structures liberated after microprocessor cleavage are known as  
precursor miRNAs (pre-miRs) and are of ~70nt in length. Pre-miRNAs are recognized 
and transported out of the nucleus by the RAN-GTP dependent karyopherin, 
Exportin-548 (Figure 2). In the cytoplasm, pre-miRs are recognized and cleaved by 
DICER49,50 which removes both the terminal base pairs and the apical loop, producing  
~22 nt miRNA duplexes. This activity  is parallel to the role that DICER has in siRNA 
maturation, where its activity was first described50.  
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Once formed, the miRNA duplex is incorporated into a protein of the argonaute 
family (AGO) to form the RISC, which is the effector complex responsible for gene 
silencing3. Loading of the duplex occurs with the assistance of HSC70/HSP90 
chaperones, which use ATP to mediate a conformational change of AGO proteins into 
a high-energy open state that allows for the entry of bulky miRNA duplexes51. 
Subsequently, AGO unwinds the miRNA duplex and ejects the passenger strand in an 
ATP-independent manner, thus forming the mature RISC complex52. RISC loading is 
an asymmetric process, with one strand being preferentially incorporated into the 
RISC. This is determined by the thermodynamic stability at either end of the miRNA 
duplex, however this mechanism is not exact and potential for the incorporation of 
either strand exists2. 
Figure 1 Canonical biogenesis of miRNAs. Most miRNAs are transcribed by Pol II into long primary 
transcripts that are capped and polyadenylated. Pri-miRs contain stem-loop structures that in 
the nucleus are recognized and cleaved by the microprocessor complex into ~70 nt pre-miRNAs. 
These are then exported out into the cytoplasm by Exportin-5–Ran-GTP. In the cytoplasm pre-
miR undergo a second cleavage by Dicer, generating 22nt miRNA duplexes. These duplexes are 
loaded into an AGO protein where the mature strand remains in complex with AGO, forming the 
RISC, whilst the passenger strand is ejected and degraded. 
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Non-canonical biogenesis of miRNAs 
As well as the canonical two-step pathway, alternative mechanisms of miRNA 
biogenesis independent of either DROSHA or DICER have been elucidated15 (Figure 
2). The first of these involves miRNAs derived from spliced and debranched short 
introns known as ‘mirtrons’53,54. Mirtrons are generated independently from DROSHA 
and are instead processed by the spliceosome into non-linear intermediates 
subsequently resolved by the lariat debranching enzyme to adopt a hairpin 
conformation with a traditional 3’ 2 nt overhang53,54. These hairpins can then enter 
the canonical pathway at the nuclear export step functioning as Exportin-5 and DICER 
substrates54 (Figure 2 B).  
A second class of DROSHA-independent noncanonical miRNAs arise from 
endogenous short hairpin RNAs (shRNAs) directly transcribed by Pol II55,56. In this case 
the first nucleotide of the pre-miR corresponds to the transcription start site (TSS)56, 
whilst the exact mechanism of 3’ end selection remains unknown but is likely to be 
coupled to transcription termination56. The pre-miR hairpins produced in this way are 
capped at the 5’ end, which has important consequences as it impedes loading of the 
5’ mature miRNA into the RISC meaning silencing occurs exclusively through the 3’ 
strand55,56. Additionally, the nuclear export of capped precursors is mediated by 
Exportin-1 rather than Exportin-556 (Figure 2 C).  
DICER has also been implicated in the DROSHA-independent processing of miRNAs 
from other non-coding RNAs57. Examples of this include miR-1983 which arises from 
a hairpin that partially overlaps with a tRNA55 and miR-1839 which is cleaved from 
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the small nucleolar RNA (snoRNA) ACA-4558. Several reports have expanded on the 
latter, noting various examples of molecules with dual snoRNA and miRNA functions, 
uncovering a more complex relationship between different types of non-coding 
RNAs59–62 (Figure 2D). Additionally, DICER is involved in generating viral encoded 
miRNAs through atypical mechanisms30,63. 
Whilst all these examples are DICER-dependent, miR-451 is a well characterized 
erythropoietic miRNA that requires DROSHA, but not DICER64,65. In this case, the pre-
miR-541 produced by DROSHA has a very small stem, and a mature miRNA sequences 
that extends over the terminal loop65. This impedes cleavage by Dicer, and miR-451 
is instead cleaved directly by RISC component AGO2 followed by 3’ end trimming64,65 







Figure 2 Non-canonical biogenesis of miRNAs. Schematic comparing canonical and non-
canonical regulation of miRNAs. A) Canonical biogenesis of miRNA biogenesis; pri-miRs in the 
nucleus are recognized and cleaved by the microprocessor, subsequently they are transported 
into the cytoplasm by exportin-5 where they are recognized and cleaved by Dicer into mature 
miRNA duplexes. These are then loaded into AGO 1-4 to form the mature RISC. B-D) non-
canonical DROSHA independent biogenesis of miRNAs. B) mirtrons are processed by the 
spliceosome into non-linear intermediates that are resolved into hairpins by the lariat 
debranching enzyme, these then join the canonical pathway as Dicer substrates. C) 
Endogenous shRNAs are transcribed directly by Pol II and transported to the cytoplasm by 
Exportin-1 where they are processed by Dicer. Because they are capped at the 5’ only the 3’ 
strand can function within the RISC. D) miRNAs can be processed directly by dicer from 
chimeric transcripts encoding snoRNAs or tRNAs. E) Dicer independent miRNA biogenesis; 
miRNAs such as miR-541 where the mature miRNA sequence extends over the apical loop 
cannot be processed by Dicer, instead they are directly loaded and cleaved by AGO2 (the only 
AGO protein with catalytic activity). They are subsequently trimmed at the 3’ end by PARN to 
form the mature RISC.  
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MiRNA regulatory mechanisms and cellular functions 
Mechanisms of action of the RISC 
The core silencing component of the RISC consists of a miRNA bound to a member of 
the argonaute family protein (AGO); the miRNA functions as a guide whilst the AGO 
protein is the effector66–68. In humans there are 4 members of the AGO family, 
AGO1/2/3/469. These four proteins bind overlapping pools of miRNAs without an 
apparent preference66,68, however AGO2 is the only member of the family with 
conserved catalytic activity. This activity is essential for siRNA-mediated gene 
silencing as well as for non-canonical biogenesis of a small number of 
miRNAs64,65,68,70. AGO2 can also mediate endonucleolytic cleavage of mRNAs that 
show extensive binding to miRNAs, this however is a rare occurrence66,68. In fact, 
most miRNA:mRNA interactions are restricted to the  5’ end of the miRNA, requiring 
an uninterrupted stretch of at least 6 but preferably 7 binding nucleotides around 
positions 2-8 which are sufficient and necessary for regulation; this region is known 
as the ‘seed’71–73. Supplementary 3’ binding to miRNA positions 14-16 as well as the 
presence of an adenosine in position 1 can increase binding affinity for the 
mRNA4,74,75. These lenient binding requirements mean that most miRNAs are able to 
simultaneously regulate hundreds of different mRNAs5,76–79.  
The RISC induces gene silencing both by blocking translation initiation and by 
destabilisation, deadenylation and subsequent degradation of mRNAs, with 
degradation of mRNAs accounting for most of miRNA-mediated repression (66-
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90%)5–7,76–78,80–84. For the latter, the interaction between AGO and proteins of the 
GW182 family (TNR6 A/B/C in humans) is required85,86. GW182 proteins interact with 
Cytoplasmic Poly(A) binding protein (PABPC) forming a scaffold that recruits 
deadenylation complexes PAN2-PAN3 and CCR4-NOT84,87. Deadenylated mRNAs are 
then decapped by decapping protein 2 (DCP2) which functions in conjunction with 
several cofactors, including helicase DDX688,89 (Figure 3). Finally, deadenylated and 
decapped mRNAs are degraded by the main cytoplasmic nuclease, 5’-to-3’ 
exoribonuclease 1 (XRN1)89. Helicase DDX6 also interacts with the CCR4-NOT 
complex, linking deadenylation and decapping activities88. The mechanisms through 
which miRNAs mediate inhibition of translation initiation are less clear but it is 
thought they involve interference with the activity or assembly of the eukaryotic 
initiation factor 4F (eIF4F) complex. Additionally, deadenylation and decapping of 
mRNAs decreases their translation efficiency84. 
Figure 3 Mechanism of action of the RISC. Schematic representation of mechanisms of RISC 
silencing. The RISC directly interferes with the eIF4F initiation complex, in so repressing 
translation initiation. However, the majority of the silencing effects of the RISC are explained 
by deadenylation, decapping and degradation of mRNA targets. The RISC interacts with 
GW182 proteins which also bind PABPC and recruit deadenylating complexes PAN2-PAN3 and 
CCR4-NOT1. Additionally, GW182 proteins recruit decapping enzyme DCP2. CCR4-NOT1 
interacts with cofactor DDX6, through which it can establish a physical interaction to DCP2. 
Deadenylated and decapped mRNAs will be degraded by cytoplasmic exonuclease XRN1. 
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Cellular functions of miRNAs 
MiRNAs are implicated in virtually every cellular pathway during development and 
homeostasis. Strong evolutionary conservation of both miRNAs and their target sites 
highlights their vast importance, however the repressive effect of a miRNA on a single 
gene tends to be modest (< 2-fold) and deletion of individual miRNAs can often result 
in no discernible phenotype78,90,91. But whilst miRNAs do not exhibit strong repression 
of individual targets, they are able to exert their functions on hundreds of targets 
simultaneously, many of which are expressed either in close spatial or temporal 
proximity to their regulating miRNA91. Additionally, different miRNAs possess 
overlapping targets and when expressed in the same cell this allows a higher level of 
target repression whilst generating functional redundancy, dampening the effects of 
loss of individual miRNAs90–92. Taken together, all of this suggests that miRNAs usually 
function by conferring robustness to gene regulatory networks as well as fine-tuning 
the levels of co-expressed proteins rather than functioning as molecular 
switches90,91,93.  
This ability to confer robustness to a gene regulatory network is particularly 
important during development and differentiation, where miRNAs not only help 
define but also maintain differentiated cellular states by targeting unwanted 
transcripts93. An example of such is miR-124, which is repressed in neural progenitors 
with its levels increasing during neurogenesis91,94–97. MiR-124 targets multiple non-
neural transcripts, including transcripts that are highly expressed in neural 
progenitors such as laminin-γ1 and integrin-β196, as well as Sox9 which preferentially 
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drives differentiation into glial cells from neural progenitors96. In this way, miR-124 
ensures the repression of any non-neural transcripts that may still be present during 
neurogenesis, reinforcing a neuronal gene programme.  
An important miRNA family in differentiation is the let-7 family. Let-7 was originally 
identified as a heterochronic gene in C. elegans where it reaches its maximum 
expression in the last larval stage, and helps regulate the transition to adulthood8,98. 
In mice and humans, the let-7 family consists of 13 mature miRNAs with a conserved 
seed sequence that originate from 10 different precursors (let-7-a1, -a2, -a3  
(human), -b, -c(1), -c2 (mouse), -d, -e, f1, -f2, -g, -i and miR-98)99. In mammals, let-7 
family members are absent from embryonic stem cells (ESC) as their processing is 
blocked by pluripotency factor Lin28, however they are broadly expressed across 
somatic tissues100–103. Let-7 miRNAs drive lineage differentiation by silencing many 
pluripotency-and self-renewal factors including Lin28104. This capability was 
confirmed in mouse Dgcr8¯/¯ ESC which are unable to silence self-renewal 
programmes. Introduction of let-7 into these cells rescues their ability to silence self-
renewal104. Furthermore, inhibition of let-7 in mouse embryonic fibroblasts (MEF) 
promoted their de-differentiation. Reciprocally, when ESC-enriched miR-294, miR-
295 and miR-291 where introduced together with let-7, they blocked its self-renewal 
silencing potential by indirectly activating self-renewal genes104. This is illustrative of 
how multiple miRNAs act upon the same pathways, and it is their coordinated action 
that helps determine cellular outcomes.  
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As well as helping control neural development, miRNAs regulate adult brain function. 
Approximately 70% of all miRNAs are expressed in the brain, with half of 
tissue-enriched/specific miRNAs being  found in the brain105,106. They are important 
in neural maintenance, and inactivation of DICER in various brain regions leads to 
neurodegeneration107. In addition, various miRNAs co-ordinately regulate synaptic 
plasticity by exerting both promoting and inhibitory functions in pathways necessary 
for synaptogenesis and synaptic maintenance108. 
The ability of miRNAs to confer robustness to gene networks also makes them good 
at buffering environmental changes, making them important regulators of metabolic 
homeostasis21. They are key regulators of lipid metabolism with several miRNAs 
including miR-33 and miR-122 regulating the expression of numerous genes involved 
in lipid synthesis and homeostasis, fatty acid oxidation and cholesterol synthesis and 
export109,110. Additionally, miRNAs also play important roles in glucose metabolism 
by regulating insulin synthesis, secretion and sensitivity111–113. Specifically, miR-375 is 
enriched in pancreatic β-cells where it has several fundamental roles, influencing 
insulin expression114, glucose-dependent insulin secretion112, and β-cell adaptative 
proliferation115. On the other hand,  miR-103 and miR-107 are mediators of hepatic 
insulin sensitivity through direct regulation of caveolin-1 a critical regulator of the 
insulin receptor116.  
Their ability to respond to environmental changes also means miRNAs are emerging 
as important components of the immune response117. The innate immune response 
involves upregulation of various miRNAs, such as miR-155 and miR-146, miR-147, 
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miR-21 and miR-9, which are transcriptionally regulated by similar factors to 
inflammatory genes118–123. These miRNAs can target pro-inflammatory signalling 
molecules creating negative feedback loops and ensuring a timely resolution of the 
inflammatory response119,124. Additionally, miR-155 has been shown to fine-tune the 
levels of multiple immune-related genes including cytokines, chemokines and 
transcription factors125. In contrast, miR-155 has also been shown to positively 
regulate inflammatory pathways in some situations, contributing to the 
establishment of a more robust immune response126. This again shows the 
importance of cellular context on miRNA function. Downregulation of miRNAs can 
also be important in modulating the immune response; activation of interferon 
response has been shown to alter microprocessor binding to pri-miRs, leading to less 
efficient processing and reduced mature miRNA levels. This in turn leads to increased 
levels of IFN-β which again, is key in establishing a robust interferon response127. 
These are just some of the many roles that miRNAs play within cellular regulation, 
many of which we are awaiting uncovering. These roles can be hard to elucidate as 
they often operate within complex networks which lead to loss/gain of function 
studies producing very subtle phenotypes92. Furthermore, some miRNAs are not 
essential under normal conditions, but are necessary in the response to stress90,92. 
An example of this is cardiac-specific miR-208. MiR-208¯/¯ mice have close to normal 
hearts with no obvious defects, however they do not exhibit cardiac hypertrophy in 
response to various stresses, as seen in WT mice, meaning miR-208 could have a role 
in enhancing cardiac function during heart disease128. 
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MiRNAs in disease 
Because of the multitude of roles that miRNAs play in a cell, it is unsurprising that 
disregulation of miRNAs is associated with a myriad of pathologies. Changes in miRNA 
levels have been particularly well documented in different types of cancer. In general, 
cancer presents a global downregulation of miRNAs17. This is attributed to various 
factors, including genetic loss129, changes in epigenetic regulation130, defects in the 
miRNA biogenesis pathway131 and dysregulation by aberrantly expressed 
transcriptions factors such as common oncogene, MYC132, or tumour suppressor 
p53133. Downregulated levels of DICER have been observed in various tumour types 
and are associated with poor prognosis134–136. Constitutive upregulation of MYC is 
common in cancer, where it is involved in extensive reprograming of miRNA patterns, 
inducing widespread repression of miRNAs132. On the contrary, most cancers exhibit 
loss of function of p53, which is a transcriptional activator for a subset of miRNAs that 
present downregulated levels in various types of tumours133. 
Accompanying global downregulation, select upregulation of oncogenic miRNAs 
(oncomirs) is also a signature in cancer. For instance, MYC not only causes extensive 
miRNA downregulation but is responsible for driving expression of the oncogenic 
miRNA cluster miR-17~92137. Overexpression of this cluster is found in various types 
of cancer and enhances cell proliferation and angiogenesis17,138–140. Of the 6 miRNAs 
in this cluster, miR-19 has the strongest tumorigenic effect by repressing tumour 
suppressor PTEN, which has roles in inhibiting proliferation and promoting 
apoptosis141. However, miR-17 and miR-20a also contribute to the cluster’s 
oncogenic effects by targeting p21 and inhibiting oncogenic-induced senescence142, 
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showing how multiple members of a cluster can potentiate its effects by 
simultaneously targeting different signalling pathways. MiR-21 is another oncomir 
found upregulated in most tumour types143,144. Mir-21 targets  multiple genes 
involved in tumorigenic processes including important tumour suppressors p53 and 
PTEN144. Furthermore, forced overexpression of miR-21 was sufficient to induce 
lymphoma in a mice model145.   
Conversely to oncomirs, some miRNAs behave as tumour suppressors. The let-7 
family of  miRNAs have established roles as tumour suppressors and are frequently 
downregulated in various cancer types, this is associated with a poor prognosis146. 
This downregulation is driven by the re-expression of LIN28A and LIN28B which are 
usually confined to early development where they block processing of let-7147. Two 
major targets of let-7 that confer it its tumour suppressor activity are oncogene RAS 
and chromatin associated protein HMGA2 which functions as a transcriptional 
regulator, contributing to proliferation and metastasis146. Another example of a 
tumour suppressor miRNA, is miR-7 which inhibits key oncogenic processes in various 
types of cancer, including cell survival and proliferation and metastasis148, and is 
frequently found to be downregulated in glioblastoma149. 
Aside from cancer, changes in expression levels of miRNAs are also associated with 
metabolic diseases. Several studies have found the upregulation of diverse miRNAs, 
including miR-143, miR-335 and miR-103/107, in obese mice116,150–152. Additionally, 
studies in both cell lines and murine models have shown levels of specific miRNAs, 
including miR-34a miR-146, miR-122 and miR-335 to be altered in various diabetic 
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models153. Supporting this, a pancreas-specific deletion of Dicer1 in mice was shown 
to produce severe defects in pancreatic development, with insulin-producing β-cells 
being the most affected154. Because of their extensive roles in regulating lipid and 
glucose metabolism, miRNAs are involved in all stages of non-alcoholic fatty liver 
disease (NAFLD), with patients exhibiting alterations in the levels of multiple 
miRNAs155. MiR-34a has proven particularly relevant both in patients with NAFLD and 
type 2 diabetes who show increased levels hepatic of miR-34a155,156.This effect seems 
to be at least partly mediated through miR-34a regulation of sirtuin 1 deacetylase 
(SIRT1) a NAD+ dependent enzyme which is a key regulator of metabolic 
homeostasis157. 
Cardiovascular disease has also been linked to aberrant miRNA expression20. Heart 
failure is preceded by pathological enlargement of the cardiac muscle, known as 
hypertrophy, which is underpinned by gene reprogramming and reactivation of fetal 
cardiac genes158. Both upregulation and downregulation of individual miRNAs leads 
to cardiac hypertrophy and subsequent heart failure through modulation of different 
pathways128,159–162. Amongst these are 2 clustered miRNAs, miR-133 and miR-1, 
which target various genes involved in cardiac function and which show decreased 
levels in models of cardiac hypertrophy160,163–165. Inhibition of miR-133 induces 
pronounced hypertrophy160 and overexpression of either miRNA shows 
cardioprotective effects and inhibition of hypertrophy160,164. Downregulation of 
another miRNA, miR-25, leads to the re-expression of developmental transcription 
factor HAND2 which also results in cardiac hypertrophy159. On the other hand, 
elevated levels of miR-25 lead to impaired Ca2+ uptake during contractions, via 
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negative regulation of a calcium transporting ATPase166,167. Impaired Ca2+ uptake is 
another hallmark of heart disease, meaning both downregulation and upregulation 
of miR-25 are associated with heart failure, highlighting the complexity of miRNA 
regulatory networks in multifactorial diseases. MiRNAs can also have a positive effect 
in reducing atherosclerosis, by regulating differentiation and proliferation of vascular 
smooth muscle cells168 and endothelial cells169, the two major cell types in veins and 
arteries. MiRNAs have also been implicated in other cardiac disease associated 
processes such as cardiac regeneration following injury170, disruptions of cardiac 
rhythm171 and regulation of cardiac fibroblasts172. 
A downregulation of several miRNAs has been observed in patients with Alzheimer’s 
disease (AD) compared to age matched controls173. Amongst the targets of these 
miRNAs are the β-amyloid precursor (APP) and the enzyme that cleaves it, β-
Secretase (BACE), generating plaques of β-amyloid as well as cofilin which 
contributed to the formation of neurofibrillary tangles (NFT)173–175. β-amyloid plaques 
and NFT represent two major characteristics of AD brains. Differences in miRNA 
profiles have also been observed in multiple sclerosis176, bipolar disorder177 and 
schizophrenia178,179 were the upregulation of several miRNAs could be attributed to 
increased pri-miRNA processing associated with increased expression of DICER178 or 
microprocessor components179. Loss of DICER and DGCR8 has also been associated 
with loss of dopaminergic neurons in Parkinson’s disease (PD)180. Additionally, many 
miRNAs, which target genes linked with PD pathogenesis or neuroinflammatory 
response, appear dysregulated in PD. In particular, downregulation of brain enriched 
miR-7 in PD has been observed; miR-7 downregulates the neuroinflammatory 
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response as well as directly regulating SNCA which encodes α-SYN, a protein involved 




Evolution of miRNAs 
Basic RNAi machinery consisting of a Dicer-like and an Ago-like protein is found in all 
kingdoms within the eukaryotic domain, suggesting it has been present since the last 
eukaryotic common ancestor181. Whilst this machinery has been lost in specific 
lineages, other eukaryotes have built from that basic pathway acquiring additional 
regulatory mechanisms that led to miRNAs182. MiRNAs have also been detected in 
various kinds of DNA viruses, with over 400 viral miRNAs annotated31,183,184.These 
miRNAs represent viral transcripts that have evolved to be able to serve as substrates 
for the cellular miRNA processing machinery, and can regulate both host and viral 
targets31,185. 
Although both plants and animals share widespread regulation by miRNAs, there are 
important differences between them suggesting that their miRNA pathways have 
evolved independently186.  Stem-loop precursors in plants tend to be both longer and 
more variable in structure than animal precursors187 and are processed by Dicer in 
the nucleus whilst animal DICER processing is restricted to the cytoplasm188. 
Additionally, plant miRNAs tend to show extensive and near-perfect 
complementarity to their mRNA targets189,190, as well as relying primarily on target 
cleavage as their mechanism of action both of which are rare in animals4,191,192.  
Within the metazoan kingdom a core of 30 miRNAs have been identified across 
bilaterians and were likely present in the last ancestor to all Bilateria193. These 
represent a first burst of ‘evolutionary innovation’ where there was a faster than 
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usual increase in the generation of new miRNA families194,195. Two other such bursts 
have subsequently taken place, the first at the base of the vertebrate lineage and a 
second at the lineage leading to eutherians194–196. This expansion of the miRNA 
repertoire is an ongoing process, exemplified by the presence of lineage specific 
miRNAs in rodents and primates195,197,198. A direct correlation has been repeatedly 
found between the number of miRNA families and morphological complexity 
suggesting miRNAs could be an important factor in the emergence of more complex 
organisms193–197. 
Along with the continuous addition of miRNAs to the genome, high conservation of 
sequence and rare secondary loss are three distinguishing characteristics of miRNA 
evolution194,196,197. The acquisition of novel miRNA families occurs through various 
mechanisms including duplication events, de novo generation and evolution of 
intronic sequences194. Non-local duplications arise either from genome wide 
duplications or from transposable elements194,199, meanwhile tandem duplications 
occur locally and are especially common in miRNA clusters. The abundance of 
hairpins as secondary RNA structures also facilitates the generation of de novo 
miRNAs194,197. These structures are not likely to arise with all the characteristics 
required for precise DROSHA and DICER processing but rather undergo gradual 
evolution into a true miRNA structure197. As such, intermediates lacking some of 
these characteristics have been identified in the human genome200. Many miRNAs, 
especially younger ones, are found in introns of protein coding genes. This is thought 
to be evolutionarily advantageous as it bypasses the need for evolution of a promoter 
23 
 
unit195,201. The same holds true for miRNA clusters, as they are usually transcribed as 
a single polycistronic unit201. 
MiRNAs also shape the evolution of their target mRNAs both by conservation and 
non-conservation of target sequences in their 3’ UTRs. Genes that are expressed in 
the same tissue as a miRNA, but in a different temporal pattern show high 
conservation of complementary sequences in their 3’ UTRs91,202. Contrarily, mRNAs 
that are expressed at the same time and place as a miRNA selectively avoid 
complementary sequences, generating what are known as “anti-targets”91. This 
selective avoidance has also had an impact on 3’UTR length with housekeeping genes 




MiRNA organisation in the genome 
MiRNAs are found both in an intragenic and intergenic context. Intragenic miRNAs 
are those mapped to regions corresponding to previously annotated genes203 and 
they represent over half of annotated human miRNAs204–206. These can be further 
classified into intronic and exonic miRNAs, with approximately 90% of intragenic 
miRNAs found in introns204,207 and over 80% of intragenic miRNAs are found in the 
same strand as their host genes204–206. Most exonic miRNAs are confined to non-
coding 3’ and 5’ regions204. With a few exceptions, intragenic miRNAs are mostly co-
expressed with their host genes and are under their transcriptional control207–209. On 
the contrary, intergenic miRNAs are independent transcription units with their own 
promoters and core transcriptional elements, which share the same characteristics 
as those of protein-coding genes210,211 (Figure 4). They possess clearly delimitated 
transcription start and termination sites211. MiRNAs are often found in clusters10–12; 
approximately 30% of mouse and 20% of human miRNAs are found less than 10kb 






Figure 4 Genomic organization of miRNAs. Diagram showing different organization of miRNAs 
within the genome. Black arrows represent promoter sites. A-B) Intergenic miRNAs are found 
between two genes and are under transcriptional control of their own promoter. C-D) Both 
individual and clustered miRNAs can be found in introns of protein coding genes and non-
coding genes. The miRNAs are usually under the transcriptional control of their host genes. E) 
MiRtrons span the entire length of an intron and are processed by the splicing machinery. F) 
MiRNAs can also be found in exons of protein coding genes and non-coding genes, usually 
confined to non-coding 3’ and 5’ regions. 
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MiRNA clusters  
MiRNA clusters range in size from two miRNAs to several dozen miRNAs. They can be 
classified into homogeneous or heterogenous clusters depending on whether or not 
they contain miRNAs from the same family, which share their seed sequences213. 
More than half of annotated clusters contain multiple miRNA families214,215. MiRNA 
clusters are usually transcribed as single polycistronic units24,211. While this leads to 
miRNAs from the same cluster usually having shared expression patterns, this is not 
always the case due to post-transcriptional regulation of individual miRNAs212,216. 
MiRNA clusters arise by a variety of mechanisms including tandem duplication, de 
novo hairpin formation within an existing transcript and dispersal of locally 
duplicated miRNAs into existing clusters212,217,218. Duplicated miRNAs often undergo 
sequence divergence leading to novel regulatory targets, with changes to a single 
nucleotide being sufficient to alter a miRNAs target pool105,106.  
MiRNAs in the same cluster often have overlapping gene targets, increasing the level 
of repression they can exert on a single gene or pathway. Furthermore, they tend to 
co-regulate genes in the same protein complexes or functional pathways, increasing 
connectivity within regulatory networks212,214,215,219. For instance miRNA cluster miR-
141~200c represses four separate components of a protein complex involving 
ZEB1/CtBP1 that acts as a translational repressor during differentiation219, whilst 
miRNAs in murine cluster miR-183~96~182 target four different members of the 
insulin signalling pathway220. 
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The potential of various miRNAs within a cluster to repress the same mRNAs as well 
as co-operatively targeting various components in a regulatory network has led to 
them having important roles in differentiation and development213. Examples include 
miRNA cluster miR-17~92 which is highly expressed in embryonic cell and a 
hemizygous deletion of which can lead to skeletal development defects such as 
microcephaly, short stature and digital abnormalities221,222. Additionally, this cluster 
is also important in myocardial development as several of its members target 
important cardiac progenitor genes223. MiRNA cluster miR-143/145 is enriched during 
cardiogenesis, with both miRNAs co-operatively regulating differentiation of vascular 
smooth muscle cells by targeting various factors that promote a less differentiated, 
more proliferative state224. Multiple clusters can also be involved in co-ordinated 
regulation, two functionally overlapping clusters, miR-34b/c and miR-499, target over 
200 genes related with cell fate control, brain development and cytoskeleton 
organisation which makes them essential in brain development, spermatogenesis 
and formation of motile cilia225. 
The widespread regulatory functions of miRNA clusters, also means their 
disregulation is often associated with a variety of diseases, the most studied being 
cancer213. Both oncogenic and tumour suppressing miRNA clusters are often located 
in fragile genomic locations where there are likely to undergo amplifications, 
deletions and translocations213. For example, amplification and overexpression of 
oncogenic miRNA cluster miR-17~92 is associated with several types of tumours. 
Targets of this cluster are enriched in cell differentiation, cell cycle and apoptosis 
pathways and increased expression of this cluster translates into higher proliferation 
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and inhibition of cell death226–228. Likewise, increased expression of miRNA cluster 
miR-182~96~183 promotes tumorigenesis in medulloblastoma, as the combined 
effects of these three miRNAs influence multiple biological processes concerning 
cellular maintenance, survival and migration229. In a contrary manner, deletion or 
downregulation of miRNA cluster miR-15-a/miR-16-1 is also found in numerous types 
of tumour, as these miRNAs are tumour suppressors which target proteins involved 
in cellular proliferation and oncogenesis230–232. Similarly miRNA cluster miR-497~195 
is frequently silenced in hepatocellular carcinoma, with its targets being enriched for 
cell-cycle regulators233. 
Besides its well established oncogenic potential, miR-17~92 cluster is also associated 
with age-related heart failure with various members targeting proteins involved in 
extracellular matrix remodelling234. MiRNA cluster miR-182~96~183 whose targets 
include several transcription factors that control T and B cell homeostasis and 
tolerance235, was identified to be upregulated on various lupus-prone mice models. 
MiRNA cluster miR-132/212 is downregulated since the earliest stages of Alzheimer’s 
disease, and is implicated in processes such as inflammation, synaptic function, 
structure and plasticity, and neural migration and morphology236,237. Downregulation 
of cluster miR-15/107 is also associated with Alzheimer’s disease as well as 
schizophrenia238. 
MiRNA cluster 14q32 
The largest known mammalian miRNA cluster is found on chromosome 14q32 in 
humans (12F1 in mice) and contains 54 miRNAs239, and is highly conserved across 
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eutherian mammals240. These miRNAs are within the imprinted DLK1-DIO3 genomic 
region, and are expressed exclusively from the maternal allele239,241. This imprinted 
region contains paternally expressed genes DLK1, RTL1 and DIO3 and maternally 
expressed genes MEG3 (murine Gtl2), MEG8(RIAN) and antisense RTL1 (Rtl1as). 
Additionally, the 14q32 region is rich in non-coding RNAs, hosting several long non-
coding RNAs (lncRNA) and snoRNAs241,242 (Figure 5). MiRNAs clustered in this region, 
are transcribed as a single polycistronic transcript, which is under transcriptional 
regulation of transcription factor MEF2A243,244. 
MiRNA cluster 14q32 is enriched in the brain and has important functions in brain 
development, with 14q32 miRNAs involved in dendritic growth, synaptic plasticity 
and differentiation and migration of neural progenitors243,245–248. MiRNAs in the 
14q32 cluster have also been linked to diverse pathologies including, diabetes249, 
schizophrenia250, cardiovascular disease251  and cancer252–257. 
 
 
Figure 5 DLK1-DIO3 imprinted genomic region. Genes in blue and pink are transcribed from the 
paternal and maternal alleles respectively. Arrows above/below the genes show the direction 
of transcription. Vertical lines represent miRNAs in the region; these are all transcribed from 
the maternal allele as indicated by the purple colouring. The lighter shade of pink/grey 




Despite the miRNA 14q32 cluster being transcribed as a single unit, altered 
expression levels of either specific subsets or individual mature miRNAs in this cluster 
are associated with diverse cellular processes and pathologies. For example, miR-134, 
miR-154, miR-299, miR-323, miR-337 and miR-370 are increased in developing lungs 
compared to adult lungs, but not of other miRNAs in the cluster258. Similarly, while 
miR-134 is poorly expressed in neural progenitors and upregulated in postmitotic 
neurons, miR-369, miR-496 and miR-543 show higher expression in neural 
progentitors248. In cancer, distinct miRNAs form this cluster form part of miRNA 
signatures associated with different tumour subtypes259–265. For instance, individual 
14q32 miRNAs are found in miRNA signatures associated with the estrogen receptor 
(ER), progesterone receptor (PR) and HER2/Neu (HER) status of breast tumours, 
namely miR-377 is associated PR positive tumours, miR-376 with HER positive 
tumours and miR-342 is predictive of ER positive tumours whilst miR-399 is predictive 
of ER negative tumours264.  
Another group (led by our collaborator Yael Nossent) highlighted the importance of 
miRNAs in the 14q32 cluster in neovascularization251. Reverse target prediction using 
197 genes involved in both angiogenesis and arteriogeniesis showed an enrichment 
for target sites of 27 miRNAs in this cluster. The cluster was further studied through 
microarray analysis in a murine hindlimb ischemia (HLI) model which showed an 




Regulation of miRNA biogenesis 
 
Transcriptional regulation 
Given their widespread regulatory roles as well as their strict temporal and spatial-
specific expression, miRNA biogenesis is tightly regulated at every step of their 
biogenetic pathway266,267. Transcriptional regulation marks the first stage of miRNA 
biogenesis control (Figure 6 A). Although some virally encoded miRNAs have been 
shown to be processed by Pol III30,31, most pri-miRs are transcribed by Pol II, 
producing transcripts that are both capped and polyadenylated28,29. Promoters for 
these Pol II transcribed miRNAs are similar to mRNA encoding promoters209 and as 
such are subject to regulation by the same host of Pol II regulatory factors268. MiRNAs 
found within the introns of protein-coding genes (intronic miRNAs) can either possess 
their own promoter or be co-ordinately expressed with their host genes, in which 
case they are subject to the same transcriptional regulation as them208,209,269. 
Additionally, miRNAs can target their own host mRNAs in autoregulatory 
loops93,270,271. 
Transcription factors are important in establishing tissue-specific expression patterns 
for miRNAs.  For instance, myogenic transcription factor, MyoD, binds to regions 
upstream of muscle specific miRNAs miR-1, miR-133 and miR-206 inducing their 
expression during myogenesis272,273. In a contrary manner, transcription factor REST 
inhibits the expression of brain specific miR-124 in non-neural and neural 
progenitors, and downregulation of REST during neural differentiation allows the 
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expression of miR-124 which targets many non-neural transcripts, facilitating the 
establishment of a neural identity274.  
Because of their regulatory role, miRNAs often form feedback loops with 
transcription factors. For example, miR-133b is positively regulated by transcription 
factor PITX3 which in turn contains miR-133b target sites in its 3’UTR region, forming 
a negative feedback loop during differentiation of dopaminergic neurons275. Similar 
regulatory loops are formed by RUNX1/miR-27a during megakaryocytic 
differentiation276 and c-MYB/miR-15a during hematopoiesis277. 
Alteration of miRNAs patterns in cancer often has roots in transcriptional regulation 
and several examples exist of miRNAs under the regulation of known oncogenes and 
tumour suppressors. For instance, tumour suppressor protein p53 has been shown 
to positively regulate members of the miR-34 family influencing apoptosis and cell-
cycle arrest278. Transcription factor and oncogene c-MYC is an important regulator of 
miRNA biogenesis with a predominantly repressive role in global miRNA expression132 
whilst upregulating select miRNAs such as the pro-tumorigenic miR-17~92 cluster137 
and miR-9279.  
Epigenetic regulation also influences expression of many miRNAs whose promoters 
are subject to DNA methylation280, these patterns are often found altered in 
oncogenesis281. Global silencing of miRNAs via CpG island hypermethylation has 
emerged as a hallmark of cancer282–284, contributing to proliferation and 
metastasis281,282. Consistently with miRNA expression patterns in cancer17 particular 
instances of hypomethylation also exist, for example in  the promoter of let-7a which-
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induces its expression and leads to increased proliferation in lung 
adenocarcinomas284. 
Post-transcriptional regulation of miRNAs 
Regulation of DROSHA processing  
Together with transcriptional regulation, post-transcriptional regulation of miRNAs is 
observed at various stages of their biogenetic pathway. The first of these steps 
involves the cleavage of pri-miRs by DROSHA, acting within the microprocessor 
complex. Processing efficiency by the microprocessor can be highly variable between 
miRNAs and can be important in determining mature miRNA levels285,286. 
Furthermore, primary miRNA transcripts can be several kilobases in length containing 
multiple mature miRNAs24,208 and miRNAs in these polycistronic clusters show 
differential processing allowing control of individual miRNA levels45,287,288. Here, 
secondary structure of pri-miRs can be an important factor in determining 
accumulation of mature miRNAs287,288. 
Regulation of pri-miR processing can occur via interaction of modulating proteins 
with either core microprocessor components or its many identified co-factors that 
bind to pri-miR directly32,36. Two of these co-factors, RNA DEAD-box helicases p68 
(DDX5) and p72 (DDX17), can themselves regulate the processing of a subset of pri-
miRs32,36,289, as well as interacting with a variety of regulatory factors co-ordinating a 
response to internal and external signals. For example, p68 promotes pri-miR-21 
processing in response to signalling by TGF-β and BMP family growth factors through 
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the SMAD pathway, an important process in vascular homeostasis290. On the other 
hand, the Hippo signalling pathway regulates microprocessor activity via the 
interaction of transcriptional coactivator YAP with p72, limiting its availability to 
associate with the microprocessor291. The Hippo pathway controls organ size through 
regulation of cell proliferation and survival and is often dysregulated in solid tumours, 
contributing to a global downregulation of miRNAs in cancer291. In a similar way, 
induction of p53 results in the upregulation of a subset of miRNAs in a p68/p72 
dependent manner and without a change in their pri-miR levels289 (Figure 6 C). This 
is in contrast to the transcriptional regulation of miR-34, showcasing a dual role for 
p53 in miRNA biogenesis289. Another important tumour suppressor, BRCA1 also 
increases processing of a subset of miRNAs normally downregulated in cancer 
through interaction with both DROSHA and p68292. 
Regulatory proteins can also interact directly with pri-miRNAs to either promote or 
repress their processing (Figure 6 B). One way to do this is by impeding the interaction 
between the pri-miRs and the microprocessor, as is the case of the NF90/NF45 
protein complex which is able to suppress DROSHA processing of several pri-miRNAs 
by binding to them and blocking their access to the microprocessor293–295. RBPs can 
also affect the structure and stability of the pri-miRs they interact with, for instance 
proteins HuR and MSI2 form a complex on the terminal loop of miR-7-1, a brain-
enriched miRNA, causing stabilization of the stem and subsequent repression of 
DROSHA processing296. This regulatory mechanism is vital in establishing the tissue 
specificity of miR-7 and its importance is highlighted by the observed dysregulation 
of miR-7 in glioblastomas297. It is important to note that regulation of miRNA 
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precursors very often occurs through terminal loops of miRNAs which tend to be 
highly conserved298.  
Proteins can have contrary effects on the regulation of different miRNAs. For 
example, hnRNPA1 can bind to the terminal loop of pri-mir-18a, a miRNA in the 17~92 
cluster, causing relaxation of the stem structure that enhances its processing by 
DROSHA298,299. However, when hnRNPA1 binds to the terminal loop of pri-let-7-a1 it 
has the opposite effect; blocking DROSHA processing through competition with 
splicing factor KRSP which in turn acts as a positive regulator for both DROSHA and 
DICER processing of a subset of miRNAs300,301 (Figure 6 B). This further illustrates how 
one protein can have multiple roles in RNA biogenesis.  
Regulation of Dicer processing 
After Exportin-5 mediated transport of pre-miRs, the second cleavage step occurs in 
the cytoplasm and is catalysed by DICER49,50. Pre-miR hairpins have a 3’ 2nt overhang 
and 5’ monophosphate group produced by DROSHA which are important for 
recognition and processing by DICER25,26,302, therefore modifications to both ends of 
the precursor regulate DICER function (Figure 6 D). On one hand, due to single 
nucleotide bulges in the stem, a small group of miRNAs including miR-105 and many 
let-7 family members only have a 1nt overhang at their 3’ end303. This difference is 
enough to significantly hinder DICER processing and thus these miRNAs are subject 
to regulation by terminal uridylyl transferases (TUTases) TUT7/4/2 which mono-
uridylate their 3’ ends restoring the 2nt overhang and increasing their processing by 
DICER303. Conversely, RNA methyl-transferase BCDIN3D can methylate the 5’ 
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monophosphate group of pre-miRNAs, blocking recognition by DICER and hindering 
their processing304. 
Similar to the co-factors associated with the microprocessor which assist and regulate 
DROSHA processing, DICER has two partner proteins, the HIV-1 TAR RNA binding 
protein (TRBP) and protein activator of PKR (PACT)305–307. Whilst in Drosophila, the 
homolog to TRBP (Loquacious) is essential for pre-miR processing this is not the case 
in humans266. Still, TRBP and PACT have been shown to alter the processing rates of 
certain pre-miRs as well as fine-tuning their length and potentially influencing strand 
selection308–312. 
As with DROSHA regulatory proteins can interact with pre-miRs through their 
terminal loop. Examples of this include RBM3 which enhances pre-miR association 
and processing by DICER313 and MBNL1 which competes with negative regulator 
LIN28A for binding to pre-miR-1 leading to its upregulation314 (Figure 6 E). Because of 
the conserved structure, the interactions that occur via the terminal loops of miRNA 
progenitor transcripts often take place with both pri- and pre-miRs affecting both 
DROSHA and DICER processing steps. Such is the case of previously mentioned 
KSRP301 as well as TAR-DNA binding protein 43 (TDP-43) which forms part of both 
microprocessor and DICER complexes and increases their affinity for miRNA 
precursors as TDP-43 also binds both pri- and pre-miRs315. This higher affinity leads 
to increased processing of a specific set of miRNAs, which has repercussions in neural 
outgrowth315. In a contrary manner Y-box-binding protein 1 (YB-1) can bind to the 
terminal loop of pri- and pre-miR-29b but unlike TDP-43 this interaction blocks 
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recruitment of both DICER and the microprocessor leading to a downregulation of 
mature miR-29-b316. This downregulation of miR-29b can lead to unwanted cell 









Figure 6 Regulation of miRNA biogenesis. Schematic representation of mechanisms regulating 
miRNA biogenesis. The top panel indicates the stages of the miRNA biogenesis pathway that 
are regulated by different mechanism, the encircled numbers correspond to the panels in the 
bottom. 1) Transcriptional regulation of miRNA biogenesis; most miRNAs are transcribed by Pol 
II and as such subject to regulation by Pol II regulatory factors, these can exert positive 
regulation such as MyoD on the miR-1 cluster, or negative regulation such as REST on miR-9. 
2) Regulation by factors binding pri-miRs CTL; different factors binding to the same pri-miR CTL 
can have opposite effects on DROSHA processing depending on context. For example, hnRNP 
A1 is a negative regulator of pri-let-7a processing and is a competitor of positive regulator 
KSRP. The same protein can also have opposite effects on the processing of different pri-miRs 
as is the case of hnRNP A1, which contrary to its negative effects on pri-let-7a processing 
enhances processing of pri-miR-18. 3) Regulation of the microprocessor; proteins that interact 
with the microprocessor core or its cofactors can negatively or positively impact the processing 
of pri-miRs. Helicases p68 and p72 are microprocessor cofactors that can regulate a subset of 
miRNAs, additionally SMAD and p53 positively regulate pri-miR processing through interaction 
with these cofactors. On the contrary, transcriptional coactivator YAP sequesters p72 hindering 
microprocessor activity. 4) Modification of pre-miRs; 5’ monophosphate groups and 3’ 2nt 
overhangs are necessary for Dicer recognition of pre-miRs, BCDIN3D can methylate the 
monophosphate group of certain pre-miRs preventing Dicer recognition and processing. 
Conversely, TUTase4/7/2 can facilitate the processing of pre-miRs that lack the 2 nt overhang 
through their mono-uridylation. 5) Regulation by factors binding pre-miRs CTL; similarly, to pri-
miRs, regulatory factors interact with pre-miR terminal loops affecting miRNAs positively or 
negatively, for example positive regulator MBNL1 competes for binding of pre-miR-1 with 
Lin28a which negatively regulates pre-miR-1 biogenesis through a uridylation dependent 
mechanism 6) RNA editing; conversion of adenine to inosine by ADARs can affect both DROSHA 
and Dicer processing as well as altering the seed sequence, generating a new pool of miRNA 
targets. 7) Regulation of miRNA turnover rate; miRNAs tend to be stable with a half-life of 
several hours to several days however mechanisms exist to accelerate their degradation. For 




Lin28 regulation of let-7 biogenesis 
One of the best characterized examples of miRNA biogenesis regulation, acting at 
both DROSHA and DICER processing steps, is the regulation of the let-7 miRNA family 
by LIN-28. Members of the let-7 family are important regulators of developmental 
timing8 with known tumour suppressor roles268,317,318 frequently found dysregulated 
in certain types of cancer99,319. During development, pri-let-7 levels remain constant, 
but mature let-7 is absent in mouse and human embryonic stem cells, increasing its 
levels upon differentiation106,320,321. This is due to pot-transcriptional regulation by 
Lin28. Lin28 is an important pluripotency factor, found to be one of four factors 
sufficient for reprogramming induced pluripotent stem cells322. Contrary to let-7, 
Lin28a is widely expressed in undifferentiated cells, where it inhibits maturation of 
let-7 and as differentiation progresses expression of Lin28 is lost allowing for a rise in 
levels of mature let-7323. 
In mammals, there are two LIN28 homologs, LIN28A and LIN28B324. These present 
some differences in their regulation of let-7;  both LIN28A and LIN28B are able to bind 
a conserved motif (GGAG) in the terminal loop of let-7 precursors which directly 
blocks DROSHA100,101 and DICER102,325,326 processing. However, the main mechanism 
action of LIN28A (but not LIN28B) involves the recruitment of a terminal uridylyl 
transferase, either TUT4 or TUT7, following its association with pre-let-7327,328. 
TUT4/7 catalyses the addition of a poly(U) tail to the 3’ end of pre-let-7 which 
impedes cleavage by DICER and serves as a marker for degradation by the 3’-5’ 
exoribonuclease DIS3L2329,330 (Figure 7). Additionally, our group has shown that E3 
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ubiquitin ligase TRIM25 is required as a cofactor in the LIN28A/TUT4 regulatory 
pathway providing an example of a newly characterized RNA binding protein331 .  
 
Other mechanisms of miRNA regulation 
RNA editing, carried out by adenosine deaminases acting on RNA (ADARs), is another 
form of regulation of miRNA biogenesis. ADARs convert adenosines in editing sites 
into inosine, modifying the stability and structure of miRNAs and hindering or 
promoting their processing by DROSHA and DICER332–335. Furthermore, if the site of 
RNA editing lies within the mature miRNA sequence an AI conversion results in a 
new set of targets being regulated217,218,220. RNA editing can be tissue specific and is 
particularly widespread in the brain, helping establish expression patterns of 
Figure 7 LIN28 regulation of pre-let-7. Schematic representation of the regulation of pre-let-7 
processing by Lin28. Lin28b mainly acts in the nucleus blocking Drosha processing. Lin28a mostly 
localizes to the cytoplasm where it directly blocks Dicer processing. Additionally, Lin28a mediates 
the recruitment of TUT4/7 which leads to uridylation of pre-let-7 3’ end and subsequent 
degradation by exonuclease Dis3l2. 
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miRNAs205,208,209. ADARs are also able to regulate both DROSHA and DICER processing 
steps in an editing-independent manner333,339,340 (Figure 6 F). 
Finally, regulating the turnover rate of mature miRNAs is another way to control their 
levels. In general, miRNAs are inherently stable molecules that can persist in the cell 
for several hours or even days341,342. However, persistence of miRNAs in the cell can 
also be subject to active regulation, either by accelerated degradation or stabilization 
of mature miRNAs. One way to influence miRNA stability is through adenylation. 
Hepatic miRNA, miR-122, is frequently adenylated by GLD-2 polymerase which 
stabilizes it343. In contrast, during infection, a virally encoded polymerase ,VP55, also 
adenylates host miRNAs facilitating their degradation344. This shows that stability of 
miRNAs is dependent on their context. Rapid degradation of miRNAs has also been 
described for other cellular processes including cell-cycle progression, growth-factor 
stimulation and neuronal activity345. Furthermore, highly complementary mRNA 
targets can induce degradation of miRNAs through a tailing and trimming mechanism 





Interplay between miRNA regulation and cellular metabolism 
 
Metabolic enzymes as novel RNA binding proteins  
 
Most of the proteins so far identified as regulators of miRNA biogenesis are well-
known players in RNA metabolism with well characterized RNA-binding motifs. 
However, in the last few years proteome-wide studies have led to the discovery of 
many novel RNA binding proteins without traditional RNA-binding motifs348–351. One 
group of proteins whose regulatory roles have traditionally been overlooked but are 
now emerging both as RNA-binding proteins and regulators of cellular processes are 
metabolic enzymes348–352. Throughout the last three decades, studies have 
increasingly identified metabolic enzymes as RNA binding proteins352–354. Metabolic 
enzymes show tissue specificity as their expression profiles vary depending on 
cellular identity352. Additionally, the levels of these proteins are altered in periods of 
fasting and in response to day/night cycles via nuclear hormone receptor signalling 
pathways355–358. This means enzymes could provide a link between gene regulation 
and environmental cues. Enzymes that exhibit secondary functions, not related to 
their catalytic activities, are sometimes called ‘moonlighting enzymes’359.  
Targets for these enzymes are diverse with some of them, such as thymidylate 
synthase (TS), catalase and dihydrofolate reductase (DHFR) binding their own mRNAs 
and forming autoregulatory loops353. Meanwhile, enolase 1 (ENO1) and serine 
hydroxy-methyltransferase 2 (SHMT2) each bind different sets of hundreds of 
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mRNAs, the difference between their targets showing they have some degree of 
binding specificity351. 
The RNA-binding activity of moonlighting enzymes can be controlled via the 
availability of metabolites. The best understood example of a protein switching 
between its catalytic and RNA-binding activities in response to metabolic cues is 
cytosolic aconitase/iron regulatory protein 1 (IRP1)360–362. When cells have high iron 
supplies, IRP1 is coupled with a Fe-S cluster which confers it aconitase activity, 
catalysing the conversion of citrate into isocitrate. However, in iron-depleted cells 
IRP1 does not possess this catalytic cluster and so functions as an active RNA-binding 
protein363. Active IRP1 binds to iron regulatory elements (IREs) controlling the 
expression of genes related to iron metabolism, for instance it simultaneously inhibits 
the translation of ferritin mRNA and the degradation of transferrin receptor mRNA 
by binding to IREs in their UTRs361. 
For some moonlighting enzymes, metabolite availability regulates their RNA-binding 
activity through direct competition. This is the case of several enzymes including 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), lactate dehydrogenase (LDH), 
alcohol dehydrogenase (ADH) and phosphoglycerate kinase (PGK) which require 
mono- or di-nucleotides as coenzymes235,242,243. For these enzymes, RNA-binding 
occurs through their structurally conserved (di)nucleotide binding domain (known as 
a Rossmann fold) such that coenzyme binding inhibits their RNA-binding 
activity354,364,365. RNA-binding enzymes containing Rossmann folds have a preference 
for AU rich-elements (ARE)364 which are important in regulating mRNA decay and 
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rates of translation and are frequently found in lymphokine, cytokine and proto-
oncogene mRNAs366,367. An additional switch-mechanism for GAPDH functions in T-
cell activation which is dependent on the transition from oxidative phosphorylation 
to aerobic glycolysis has also been described368. When T-cells are utilizing oxidative 
phosphorylation GAPDH is free to bind and ARE in the 3’UTR of IFN-γ repressing its 
translation. However, when T-cells become active they switch to glycolysis and 
GAPDH becomes engaged in the glycolytic pathway leading to the upregulation of 
IFN-γ and subsequent cytokine production. 
Not all enzymes show mutually exclusive catalytic and RNA-binding functions. AUH is 
an RNA-binding protein with enoyl-CoA hydratase activity, it catalyses the conversion 
of HMG‐CoA to 3‐MG‐CoA in leucine catabolism369,370. Like (di)nucleotide binding 
enzymes AUH binds AREs, however it does not possess a Rossmann fold or any 
traditional RNA-binding motifs369,371. Instead, a region of 20 amino-acids containing 
evenly spaced Lys residues forming a “Lysine comb” is sufficient for RNA-binding. This 
region is distinct from the catalytic site permitting RNA-bound enzyme to be active369. 
AUH is a mitochondrial enzyme localized to the inner membrane via its interaction 
with mitochondrial ribosomes372. Here, it modulates mitochondrial translation in 
addition to metabolizing leucine providing a link between mitochondrial metabolism 
and gene regulation372.  
Other mitochondrial metabolic enzymes also have shown RNA-binding capability354. 
Hydroxysteroid 17-Beta Dehydrogenase 10 (HSD17B10) is a multifunctional enzyme 
that oxidises various fatty-acid, alcohol, and steroid substrates and additionally 
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functions as part of RNAse P,  a complex required for maturation of mitochondrial 
transcripts373,374. Trifunctional-enzyme subunit β (HADHB) is required for oxidation of 
fatty acids but can also bind renin mRNA, decreasing its stability375. Similarly, 
isocitrate dehydrogenase (IDH) binds to eight major mitochondrial mRNAs376, with 
this binding inhibiting its enzymatic activity allosterically377. 
Many identified moonlighting metabolic enzymes still await in vivo validation as well 
as elucidation of the function and physiological relevance of their RNA-binding 
activities. So far, research has mostly been focused on the interaction of metabolic 
enzymes with mRNAs however it is tempting to consider that these proteins could 
also be interacting with another network of important gene regulators; miRNAs. We 
are still uncovering novel participants in miRNA regulatory pathways and with the 
increasing elucidation of their regulatory roles, metabolic enzymes are good 
candidates especially when we consider miRNAs are key participants in metabolic 
homeostasis21. 
Regulation of RNA binding activity by cellular metabolites 
RNA-binding activity of moonlighting enzymes is commonly regulated by cellular 
metabolites that function as their substrates or co-factors either through direct 
competition or allosterically352. However, cellular metabolites have the potential to 
regulate RNA-binding activity of proteins other than their natural enzymes. This 
regulation can happen indirectly, by influencing post translational modifications. 
Protein acetylation is dependent on the cellular availability of acetyl-coA, a 
metabolite which is also necessary for the synthesis of various molecules378. Many 
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proteins including both metabolic enzymes and traditional RBPs undergo acetylation, 
and acetylation of RNA-binding proteins can influence their RNA-binding 
potential352,378–381.  
Metabolites regulation can also happen directly, for example the RNA-binding activity 
of translation regulator Mushashi-1 (MSI1) is allosterically regulated by oleic acid 
(OA), an 18 carbon ω-9 mono-unsaturated fatty acid340. OA binds to the RNA-binding 
domain of MSI1, changing the environment surrounding amino acids critical for RNA-
binding. Other 18-22 carbon cis ω-9 mono-unsaturated fatty acids can inhibit MSI1 
binding, however closely related elaidic acid, which is also a ω-9 mono-unsaturated 
fatty acid but with a trans bond cannot. MSI1 in turn, regulates the expression of 
stearoyl-coA desaturase, an enzyme which catalyses the conversion of saturated fatty 
acids into mono-unsaturated fatty acids. In this way MSI1 acts as a metabolite sensor, 






The biogenesis of miRNAs is constantly regulated in response to the cellular and 
extracellular environments, allowing for their controlled production in temporal and 
spatial specific manners. This regulation is the result of multiple interacting factors 
that act on all stages of the miRNA biogenesis pathway to fine-tune the levels of 
mature miRNAs. There are still many unknown components in these regulatory 
networks and as our knowledge of RNA binding proteins expands, novel mechanisms 
of miRNA biogenesis will continue to emerge.  
This study focused on unravelling the mechanisms and factors behind the 
post-transcriptional regulation of miRNAs. The experiments were carried out to 
elucidate the details of miRNA biogenesis regulation in three specific contexts with 
the following aims: 
1. Post-transcriptional regulation of miRNA cluster 14q32; 
 Identifying protein factors binding to 14q32 miRNA precursors differentially 
regulated during ischemia. 
 Validating proteins identified as binding to 14q32 pre-miRNAs  
 Exploring the expression of these proteins in a murine hindlimb ischemia 
model 
 Determining the effects of altering the levels of these proteins in a NIH-3T3 
serum starvation model 




 Determining the Lin28a domains involved in its binding to pre-let-7-a-1 and 
pre-miR-9 
 Exploring the regulatory effect of constitutive expression of Lin28a on  other 
miRNAs during neurogenesis 
3. Inhibitory effect of oleic acid on regulation of miRNA biogenesis by RBPs. 
 Evaluating the effect of oleic acid (OA) and elaidic acid (EA) on pre-miR-
7/protein complexes 
 Determining the effect of OA and EA on in vitro processing of pri-miR-7 





Materials and methods 
Cell culture 
 
P19, HeLa (ATCC) and NIH-3T3 (ECACC) cells where grown under standard conditions 
( 37°C and 5% CO2) in DMEM growth media (GIBCO) supplemented with 10% Foetal 
Bovine Serum (GIBCO) unless otherwise indicated. Cells were passaged at 80% 
confluence using TrypLE express (GIBCO).  
P19 cell lines with stable expression of Lin28a-GFP or GFP-only were gifts from Dr. 
Eric Moss (Rutgers School of Biomedical and Health Sciences, formerly The University 
of Medicine and Dentistry, New Jersey, USA). P19 cell lines stably expressing 
untagged Lin28a were previously generated in our research group using the Flp-in 
system (Thermo Fisher Scientific)383. 
Cellular serum starvation of NIH-3T3 cells 
 
For starvation experiments NIH-3T3 passaged cells were first allowed to grow for 24 
hours in fully complemented media. Following 24 hours, cells were washed twice 
with non-complemented media following which with either fully complemented 
DMEM media (10% foetal bovine serum) or media without  complementation (0.5%  
foetal bovine serum) was added. Cells where then grown for an additional 24 hours 
before experiments were carried out. 
Preparation of total protein extracts from cell lines 
 
Cells were carefully washed twice with PBS. After removing PBS cells were scraped in 
appropriate volume of Roeder D (350µl for a p100 dish, 50µl for a 6-welled plate) and 
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collected in a microfuge tube. Samples were vortexed and then sonicated in an ice 
water bath twice for 5 minutes in 30 second cycles. After sonication tubes were 
centrifuged for 10 minutes at 10,000 rpm, 4 °C. Supernatant was collected and 
samples were quantified using the Nanodrop 2000 (Thermo Fisher Scientific). 
Pre-miR in vitro transcription 
Template DNA was generated by amplifying RNA of interest with primers that 
included a T7 promoter sequence (TAATACGACTCACTATAGG). In vitro transcription 
reactions were set up in a 25μl volume which included 10μl of DNA template PCR 
product, 1.25μl of 20mM rNTPs (Roche), 0.5μl of RNaseOUT (Invitrogen) and 1μl of 
T7 RNA polymerase (NxGen T7 RNA Polymerase, Lucigen supplied at 50,000 U/mL) 
and 10μl of reagent buffer (Lucigen). Reactions where incubated for 90 minutes in a 
37°C water bath after which 2μl of TURBO DNase was added (Ambion, supplied at 2 
U/μl) and reactions were incubated a further 10 minutes at 37°C. RNA was then 
precipitated by adding 1/10 3M NaAc and 3x volume 100% ethanol and incubating 1 
hour on dry ice. Pellets were washed and resuspended in 25μl water to which 25μl of 
UEO running buffer was added. Samples were boiled for 10 minutes at 90°C before 
running on a pre-warmed 10% PAGE/UREA denaturing gel. Gels were stained using 
RNA staining solution, bands were cut out and incubated o/n in 300μl of RNA elution 
buffer. The following day RNA was precipitated by adding 900 μl 100% ethanol and 
incubating 1h on dry ice. RNA was then washed in 70% ethanol and resuspended in 




Western blot analysis  
 
Protein samples were resolved by standard SDS-PAGE electrophoresis using NuPAGE 
Bis-Tris gels run in 1X NuPAGE MOPS SDS running buffer supplemented with 1:000 
NuPAGE antioxidant (Invitrogen). Polyacrylamide concentration was 10% in all cases 
except when resolving protein extracts overexpressing Lin28a truncations, where 4%-
12% gradient gels were used. Gels were transferred for onto a nitrocellulose 
membrane (0.45µm pore, GE healthcare). The membrane was blocked overnight at 
4°C in 1:10 western blocking reagent (Roche) diluted in Tris-buffered saline (TBS) 
with 0.1% Tween 20 (TBS-T). The following day membrane was incubated for 1 hour 
with selected antibody diluted in 1:20 western blocking reagent (Roche) in TBS-T. 
Blots were washed three times for 10 minutes with TBS-T and were then incubated 
for 1 hour with corresponding secondary antibody diluted in 1:20 western blocking 
reagent (Roche) in TBS-T.  
Secondary antibodies were conjugated to horseradish peroxidase (HRP) and were 
detected with the SuperSignal West Pico detection reagent (Thermo Scientific). The 
membranes were stripped using ReBlot Plus Strong Antibody Stripping Solution 
(Chemicon) equilibrated in water, blocked in 1:10 western blocking solution in TBST, 
and re-probed as described above. 
Quantification of western blot assays 
Western blots were quantified using ImageJ analysis software (1.48v, NIH) and 




RNA pulldown assay  
In vitro transcribed RNA was prepared for coupling to the beads by activation with 
m-sodium periodate. m-Sodium periodate will specifically oxidize hydroxyl-groups 
present in adjacent carbons in RNA forming two aldehyde groups. These aldehyde 
groups will readily react with hydrazide modifications in the agarose beads forming 
stable linkages. The following activation reaction was set up in a 1.5mL screw cap 
tube; 6.7μl of 3M NaAc, 10μl of 0.1M m-sodium periodate and 1000 pmol of in vitro 
transcribed RNA in a final volume of 200μl. This reaction was incubated while rocking 
for 1h  at room temperature (RT) protected from light.  
RNA was precipitated for 30 minutes on dry ice by addition of 15μl 3M NaAc and 
600μl 100%. RNA was centrifuged for 20 minutes at full speed at 4 °C, washed in 1ml 
70% ethanol by spinning 3 min at full speed and resuspended in 500μl 100 mM 
NaOAc. 
Agarose beads (Adipic acid di-hydrazide-Agarose, Sigma-Aldrich) were prepared for 
coupling by washing thrice with 100mM NaOAc. 200μl prepared beads were added 
to the 500μ activated RNA and the coupling reaction was left protected from light, 
rocking overnight at 4 °C. The following day unbound RNA was washed out by a 30 
min incubation with 700μl 4M KCl at RT. Beads were collected by centrifugation at 
3000 rpm for 2 min. Coupled beads were then washed twice with 1ml 2M KCl and 3 
times with 1ml Buffer G. Beads were then incubated with protein extracts for 30 
minutes at 37°C whilst shaking at 400 rpm in the following reaction; 250μl protein 
extract (1000μg), 9.75μl 100mM MgCl2, 32.5μl 0.5 M CIP, 3.25μl ATP, 0.5μl 
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RNaseOUT (Invitrogen) in a volume of 650μl. Reactions were washed three times with 
buffer G centrifuging for 3 min at 1000 rpm each time. 
Proteins were then eluted in 39μl H2O, 15μl NuPAGE sample buffer (Invitrogen) and 
6μl NuPAGE sample reducing agent (Invitrogen) by boiling at 70°C for 10 minutes 
while shaking. Beads were sedimented by spinning 1 minute at top speed. 
Supernatant was then used for gel electrophoresis and analysed either  by SILAC mass 
spectrometry or western blot. 
RNA pulldown followed by SILAC mass-spectrometry (RP-SMS) 
 
SILAC labelling 
For labelling, cells were grown in SILAC ‘heavy’  and ‘light’ media for six passages 
(R6K4 ‘heavy’ and R0K0 ‘light’, DC Biosciences), supplemented with 10% foetal bovine 
serum, except for starvation conditions where they were supplemented with 0.5% 
foetal bovine serum. To verify incorporation of heavy isotopes was evaluated by 
performing Liquid Chromatography with tandem mass spectrometry (LC-MS/MS) 
using an orbitrap mass spectrometer. For this, protein extracts diluted in 1X NuPAGE 
sample buffer and 1X NuPAGE reducing agent (Invitrogen) were run in an SDS-
polyacrylamide gel, running in 1X NuPAGE MOPS SDS running buffer supplemented 
with 1:000 NuPAGE antioxidant (Invitrogen). Gel was stained with GelCode Blue safe 
protein stain (Thermo fisher scientific) and using a razor blade a 0.5-cm piece of gel 
was cut from the centre of the lane. In-gel digestion and peptide purification were 
then carried out as described below. To determine efficiency of heavy label 




Isolated gel fragments were cut into small 1mm x 1mm pieces. Gel pieces were 
transferred into a microfuge tube and incubated 5 minutes at RT with 200μl of 50mM 
ammonium bicarbonate (ABC). ABC was removed and replaced with 200μl 
acetonitrile (100%) and samples were incubated a further 5 minutes. These two steps 
were repeated until the solution was no longer blue. Sufficient 10mM DTT to cover 
the gel pieces was added  and the samples were incubated for 30 mins at 37°C. Liquid 
was removed and 200μl of acetonitrile were added for 5 min.  
In the dark, acetonitrile was removed and enough 55 mM iodoacetamide (IAA) to 
cover the gel pieces was added. IAA was removed, ABC was added for 5 min, then 
acetonitrile was added for 5 min. Trypsin buffer was prepared on ice and added to 
cover the gel pieces. These were incubated on ice for 15 minutes. More trypsin buffer 
was added to cover the gel pieces and incubate at 37 °C for 30 min. Acetonitrile/ABC 
solution was added to cover the gel pieces, which were then left at 37 °C overnight. 
A 1:1 volume of 0.1% trifluoracetic acid (TFA) was added to samples which were then 
left for 20 min. pH was adjusted to 1-3 with 10% (TFA). 
 A C18 stage tip (Sigma Supelco) was activated by pushing 20μl methanol through the 
tip. The tip was then conditioned by pushing 40μl of 0.1% TFA through the tip. Sample 
was loaded unto the tip by spinning. To wash the sample, 60μl of 0.1% TFA were 





Mass spectrometry analysis of pulldown samples  
Mass spectrometry was carried out with the help of Dr. Christos Spanos at the WCCB 
Proteomics Facility. Supernatants recovered from the beads after pulldown were run 
in an SDS-polyacrylamide gel using 1X NuPAGE MOPS SDS running buffer 
supplemented with 1:000 NuPAGE antioxidant (Invitrogen), such that the dye 
migrated 1 cm into the gel. Gel was then stained with GelCode Blue Safe protein Stain 
(Thermo fisher scientific). Bands were cut out using a razor blade and in-gel digestion 
proceeded as described above. LC-MS/MS analysis was performed using a Velos LTQ-
Orbitrap mass spectrometer. MaxQuant software platform was used to analyse the 
raw mass-spectrometry data to determine the ratio of the heavy-labelled and light-
labelled peptides. 
Hindlimb Ischemia Model 
 
All in vivo experiments on a murine model were conducted by Yael Nossent’s group 
at the Leiden University Medical Centre and approved by the Committee on Animal 
Welfare of the Leiden University Medical Centre (Leiden, the Netherlands; approval 
reference numbers 09163 and 10243). This study was conducted in accordance with 
the Directive 2010/63/EU of the European Parliament. Unilateral hindlimb ischemia 
was induced in healthy adult male C57BL6 mice by single ligation of the left femoral 
artery251,384. C57BL/6 mice (n = 4 per time point) were sacrificed at several time points 
(day 0 [before ligation of the femoral artery] and days 1, 3, 7, 10, 14, and 28 after 
hindlimb ischemia induction)385. Upon sacrifice, the adductor muscles were 
harvested and either snap-frozen on dry ice or fixed in 4% paraformaldehyde. 
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Preparation of total protein extracts from adductor muscle 
 
Total protein was isolated from adductor muscle tissue of mice on days 0, 1, and 3 
after induction of ischemia. Tissue samples were homogenized in 1 ml of TRIzol 
reagent (Invitrogen) using the QIAGEN TissueLyser II. 5mm stainless steel beads were 
used and samples underwent 2 x 60 sec pulses at 30 Hz. After homogenization of the 
sample, 200µl of chloroform was added to the samples. Tubes were shaken 
vigorously and left to stand for 2 minutes. Samples were then centrifuged at 13,000 
rpm for 15 min, 4°C. The upper clear aqueous phase was recovered and set aside for 
RNA isolation. The interphase was removed and discarded, and 1 ml of cold acidified 
acetone/methanol was added to the remaining organic phase. The samples were 
mixed and left overnight at -20°C. The next day samples were centrifuged at 6000 
rpm for 15 min at 4°C. Pellets were washed twice in 95% ethanol and air dried. 
Samples were resuspended in optimized lysis buffer K, incubating overnight at 50°C. 
Immunohistochemical Staining 
 
Experiments were conducted by Yael Nossent’s group in Leiden University Medical 
Centre. Formaldehyde-fixed adductor muscles were paraffin-embedded, and 5-μm-
thick cross-sections of muscles were stained to visualize the expression of RBPs. Cross 
sections of adductor muscles were re-hydrated, and endogenous peroxidase activity 
was blocked. Antigen retrieval was performed with citrate buffer (pH 6.0) at 100°C 
for 10 min. Muscles were stained with rabbit polyclonal anti-HADHB (Novus 
Biologicals, NBP1-82609, 1:1,000) or goat polyclonal anti-CIRBP (Abcam, ab106230, 
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1:400) to visualize HADHB and CIRBP, respectively, and counterstained using 
haematoxylin. 
Microarray analysis in hindlimb ischemia model 
 
Array analysis was performed by Yael Nossent’s group on total RNA extracted from 
adductor muscle tissue from days 0, 1, 3, and 7 after induction of hindlimb ischemia. 
For array analysis, MouseWG‐6 v2.0 Expression BeadChips (Illumina), which contain 
more than 45 200 transcripts, were used. Expression levels were log2‐transformed, 
and quantile normalized. Transcripts showing background intensity (log2 expression 
of <6.75) both at baseline and after induction of HLI, were removed from the analysis. 
RNA extraction from cell lines 
 
Cells grown in 6 well plates were carefully washed twice with PBS and subsequently 
homogenized by pipetting in an 1ml of TRIzol reagent (Invitrogen) and transferred to 
a microfuge tube. After a 5 min incubation at RT 200µl of chloroform was added, 
tubes were shaken vigorously and left to stand for 2 min. Samples were then 
centrifuged at 13,000 rpm for 15 min, 4°C. The upper clear aqueous phase was 
transferred to a new tube and 500µl of isopropanol were added, after mixing tubes 
were left to stand 10 min at RT. Samples were centrifuged again at 13,000 rpm for 15 
min, 4°C. The resulting pellet was washed with 1ml cold 70% ethanol. The pellet was 
briefly dried and subsequently dissolved in required volume of water, incubating 10 





For isolation of pre-miRNA containing fractions, total RNA was isolated as above and 
was briefly run on 10% denaturing PAGE-UREA gel until tracking dyes had separated. 
The fraction of the gel containing RNAs from 50 nt to 100 nt was cut out using a razor 
blade and incubated o/n in 300μl of RNA elution buffer. The following day RNA was 
precipitated by adding 900 μl 100% ethanol and incubating 1h on dry ice. RNA was 
then washed in 70% ethanol and resuspended in water. 
Quantification of miRNA levels by qRT-PCR 
 
MiRNA quantification was carried out as instructed using miScript Reverse 
transcription and SYBR® green PCR kits (QIAGEN). Total RNA was isolated as 
described above and 400ng were used per reverse transcription reaction. The cDNA 
was further diluted 1:3 and 2µl were used per qPCR reaction. Specific forward primers 
were used in this assay, these corresponded to the sense strand of the mature miRNA 
sequence. The reverse primer used is the miScript Universal Primer (miScript). All 
reactions were carried out with a technical duplicate and normalized against miRNA-
16.For quantification of pre-miR levels the same kits and protocols were used 
following fractionation as described above. In this case only 50ng were used per 
transcription reaction. 
Detection of miRNA precursor species in adductor muscle of mice in a hindlimb 
ischemia model were carried out by Yael Nossent with quantification performed 
using TaqMan microRNA, pre-miRNA and pri-miRNA assays (Applied Biosystems) 
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according to the manufacturer’s protocol. Relative qPCR was performed on the Viia7 
system and normalized to snRNA-U6. 
Generation of knockout cell lines using CRISPR/Cas9 
 
Introduction of guide RNAs into Cas-9 containing plasmid px458 
Target CRISPR sites in HADHB and CIRBP were identified using Sanger’s WTSI Genome 
Editing tool (https://www.sanger.ac.uk/htgt/wge/). Sequences targeting exon 1 of 
CIRBP an exon 3 of HADHB were selected. For cloning into the sgRNA scaffold in Cas9 
containing plasmid px4598 oligonucleotides for selected CRISPR target sequences 
were synthesized in the form: 
5’ – CACCGNNNNNNNNNNNNNNNNNNN           – 3’ 
   3’ –           CNNNNNNNNNNNNNNNNNNNCAAA – 5’ 
Oligonucleotides were set up in an annealing reaction as follows; 1µl of Oligo 1 
(100µM), 1µl of Oligo 2 (100µM), 1µl 10X T4 ligation buffer (NEB), 6.5µl H2O, 0.5µl T4 
PNK (NEB). The reaction was incubated in a thermocycler set for 30 min  at 37 °C,  5 
min at 95 °C and then ramp down to 25 °C at 5°C/min.  
Digestion of px458 plasmid was performed for 1 hour at 37 °C with BbsI restriction 
enzyme in the following reaction; 1µg plasmid, 1µl BbsI, 2µl 10X digestion buffer, x µl 
of H2O for 20µl final volume. Digested products were then run in a 1% agarose gel in 
1X TBE buffer and gel purified using QIAquick gel extraction kit (QIAGEN) according 
to manufacturer’s instructions. Following purification of digested vector and 
annealing of oligonucleotides, a ligation reaction was set up as follows; 50ng of BbsI 
digested plasmid, 1µl annealed oligonucleotides (diluted 1:200), 5µl 2X ligation buffer 
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(NEB), 1µl T4 ligase (NEB), x µl of H2O for a final volume of 10µl.  The reaction was 
incubated 1hour at 37 °C. The ligation was then transformed into competent bacteria 
and purified as described below.  
FACS flow cytometry of transfected NIH-3T3 cells 
Cell sorting was carried out with the help of Dr. Martin Waterfall at the IIIR/SBS Flow 
Cytometry Facility using the FACSAria cell sorter (BD Biosciences). NIH-3T3 cells were 
transfected 24 hours before preparation for sorting with 2µg of px458 plasmid 
containing desired guide RNAs, following the transfection protocol described below. 
Immediately before sorting cells transfected cells were trypsinized, centrifuged 5 min 
at 1500 rpm and resuspended in basic sorting buffer. Cells were counted and diluted 
to a concentration of approximately 15x106/ml. To achieve a single cell suspension 
and eliminate any clumping, cells were filtered by pipetting though a 40μm nylon 
mesh (Falcon) into a 50 ml conical tube.  
In preparation for collection, 50μl of fully complemented media was added to each 
well in 96-well plates. After sorting a further 50μl were added to each well using a 
multichannel pipette. Single cells were sorted into individual wells using channel 
settings to detect GFP-signal in positively transfected cells. As a sorting control, non-
transfected cells were also sorted into individual wells.  
After sorting cells were grown until single cells had developed into visible colonies, 
changing the media every 2-3 days. Once colonies were visible cells were passaged 
into 24-well plates, which were further divided into duplicate plates. One plate was 
used for cell maintenance whilst the other was used for genomic analysis.  
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Isolation of genomic DNA and amplification of target regions 
Genomic DNA was isolated using GenElute™ Mammalian Genomic DNA Miniprep Kit 
(Sigma-Aldrich). Trypsinized cells were centrifuged for 5 min at 1500 rpm and culture 
media was completely removed. Pellets were resuspended in 200μl of resuspension 
solution and transferred to a microfuge tube to which 20μl of Proteinase K solution 
and 200μl of Lysis solution were added. Samples were thoroughly vortexed and 
incubated at 70 °C for 10 minutes. 200μl of 100% ethanol were added to incubated 
samples, which were then vortexed and loaded unto a previously equilibrated 
column using a pipette tip with the end cut to avoid shearing. Samples were 
centrifuged at 7000 rpm for 1 min and then washed twice with 500μl wash solution, 
centrifuging first for 1 min at 7000 rpm and then for 3 min at 13,000 rpm. Columns 
were then transferred to new collection tubes and DNA was eluded in 200μl elution 
solution by centrifuging at 7000 rpm for 1 min.   
Genomic DNA preparations were then used as template to amplify the region 
surrounding CRISPR target sequences. Primers were designed using Primer3 to 
encompass a region between 500-1000 nucleotides surrounding CRISPR targets, 
ensuring no binding to other genomic regions. PCR amplification reactions were set 
up as follows; 1μl of genomic DNA, 2.5μl forward primer (10μM), 2.5μl reverse primer 
(10μM), 10μl 5X Phusion HF Buffer (NEB), 1μl dNTPs (10mM working mix) (Roche), 
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0.5μl Phusion® High-Fidelity DNA Polymerase (NEB) 32.5μl H2O. PCR amplification 
was conducted under the following settings: 
After amplification, 10μl of 6X purple loading dye (NEB) were added and PCR products 
were run on a 1% agarose gel in 1X TBE. Bands were cut and gel purified using 
QIAquick gel extraction kit (QIAGEN) according to manufacturer’s instructions. 
Cloning and sequencing of amplified target regions 
Purified products were cloned into pJET1.2/blunt cloning vector (Thermo Scientific) 
for sequencing. Blunt-end cloning reactions were set up as follows; 50ng of purified 
PCR product, 10μl 2X reaction buffer, 1μl pJET1.2/blunt cloning vector, 1μl T4 DNA 
ligase, x μl H2O to a final volume of 20μl.  Reactions were incubated at room 
temperature for 10 min and used directly for transformation using the protocol 
described below. Reactions were sequenced using both pJET1.2 Forward and Reverse 
sequencing primers. All sequencing was carried out at Edinburgh Genomics.  
Transient transfection of cultured cell lines 
 
For transfections, cells were plated at a confluency of ~80%. Transfections were 
carried out using lipofectamine 2000 (Invitrogen). For each transfection reaction two 
15 ml conical tubes were set up; one tube containing 245µl of OPTI-MEM media 
(GIBCO) + 5µl of lipofectamine (Invitrogen) and a second tube containing the required 
concentration of plasmid + the required volume of OPTI-MEM for a final volume of 
250µl. The typical concentration of DNA added was 500ng, however this was adjusted 
according to protein expression levels. Tubes were briefly vortexed and incubated for 
5 min at RT. Lipofectamine was then added drop-by-drop into the plasmid containing 
64 
 
tube containing for a final volume of 500µl. This reaction was incubated for 30 min at 
RT. In the meantime, cells were washed twice with OPTI-MEM media before adding 
1.5ml of fresh DMEM media supplemented with 10% FBS. Finally, the lipofectamine 
and plasmid mixture was added to the cells drop-by-drop. An additional mock 
reaction was always set up in parallel were lipofectamine was mixed into a tube 
containing 250µl of OPTI-MEM but no DNA. 
Bacterial transformation 
 
A 50µl aliquot of competent DH5α E.coli cells was thawed on ice and either 10µl of 
ligation reaction or 1µl of DNA plasmid were added to the aliquot. Tubes were gently 
mixed, without vortexing, and incubated for 30 minutes on ice.  Tubes were then 
placed in a heat block, surrounded by water for 90 s at 42 °C and immediately after 
placed in ice for 90 sec. Subsequently, 800µl of SOC media was added to bacteria and 
tubes were left shaking for 1h at 37 °C. Whilst bacteria were shaking LB agar plates 
containing appropriate selection antibiotic were pre-warmed at 37 °C. After 1 hour, 
200µl of bacteria were spread on pre-warmed LB agar plates using a shaped glass 
Pasteur pipette, sterilized with ethanol. Plates were incubated overnight at 37 °C.  
The following day, individual colonies were selected and grown in 5ml of LB broth 
with appropriate selection antibiotic. The next day plasmids were purified using 





Cloning of Lin28a truncations into T7-expression vector 
 
Lin28a truncations were cloned into an expression vector (g10) which contains a T7-
protein tag sequence. For this, Lin28a fragments were amplified using primers which 
annealed to the desired start and end sites of each Lin28a truncation. Additionally, 
all forward primers contained an XbaI restriction site and all reverse primers 
contained a BamHI site which were used for sticky-end cloning. Amplified PCR 
products were run in a 1% agarose gel and gel purified using QIAquick gel extraction 
kit (QIAGEN) according to manufacturer’s instructions. 
Digestion reactions for purified PCR products and g10 expression vector were set up 
as follows; 500 ng DNA, 1μl XbaI restriction enzyme (NEB), 1μl BamHI restriction 
enzyme (NEB), 5μl 10X NEBuffer (NEB) and H2O to 50μl. These were incubated for 1 
hour at 37 °C. Digestions were then run in a 1% agarose gel and gel purified using 
QIAquick gel extraction kit (QIAGEN). Purified and digested products were then 
ligated using T4 DNA ligase (NEB). 100ng of digested vector were used per ligation 
reaction; the amount of insert for each reaction was calculated to achieve a 3:1 insert 
to vector molar ratio. Ligations were set up as follows; 100 ng vector, x ng insert (3:1  
molar ratio), 1.5μl  10x T4 DNA ligase buffer (NEB), 0.5μl T4 DNA ligase (NEB) and x μl 
H2O for a final volume of 15μl. Ligations were incubated overnight at 4 °C. The 
following day 10μl of the ligation reaction were directly used for transformation as 
described in protocols above. Individual colonies were grown in 5 ml of LB broth 
supplemented with ampicillin and plasmid DNA was purified using QIAprep spin 
miniprep kit (QIAGEN) following manufacturer’s instructions. 
66 
 
Electrophoretic mobility shift assay (EMSA) 
 
32P-αUTP was used for internal labelling of pre-miR probes generated through 
in-vitro transcription. For this, reactions were set up as following; 10 ng of DNA 
template, 2.5μl 10X T7 reaction buffer (Lucigen),  1.25μl  of 20nM GCA rNTP mix 
(Roche), 1.25μl 1nM UTP (Roche), 0.5μl RNase out (Invitrogen), 1μl T7 RNA 
polymerase (NxGen T7 RNA Polymerase, Lucigen supplied at 50,000 U/mL) and 2.5μl 
32P-αUTP in a final volume of 25μl.  Reactions were incubated for 90 minutes at 37 °C 
and subsequently run in a 10% PAGE-UREA gel and purified as described in the 
sections above. Purified radiolabelled pre-miRs were then incubated with total HeLa 
extracts in the absence and presence of increasing concentrations of oleic acid (OA) 
and elaidic acid (EA) in the following set up; 1μl probe, 150 ng protein extract, 2μl 
solution A, 0.5μl RNaseOUT (Invitrogen), x μl of OA/EA and Roeder D for a final 
volume of 20μl. Reactions were incubated on ice for 1 hour. Following incubation 5μl 
of native loading buffer (0.02% Xylene Cyanol, 0.02% Bromophenol Blue) was added 
and samples were separated on a on 6% non-denaturing PAGE by running in 0.5 × 
TBE at 8 W. The gel was then dried and exposed to a phosphor screen overnight. The 
gel-exposed phosphor screen was scanned using a Fujifilm FLA 5000 scanner. Image 
analysis and quantitation were performed using Aida Image analyser V.4.27 software. 
Western blot-combined EMSA (WEMSA) 
For WEMSA, initial steps were carried out as described above and after samples were 
separated by PAGE, the proteins were transferred onto a nitrocellulose membrane 
and western blot proceeded as described in protocols above.  
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In-vitro processing assays 
 
In vitro processing assays were carried out by in our group by Santosh Kumar. 
Pri-mi-7-1 and pri-miR-16 were synthesized by in vitro transcription using plasmids 
containing respective sequences as templates and were labelled using 32P α-UTP. 
Radiolabelled pri-miRs (~ 30,000 cpm) were incubated with 50% HeLa cell extract in 
either the presence or absence of OA and EA, and processing was performed at 37 °C 
for 30 min with 0.5 mM ATP, 20 mM creatine phosphate, and 3.2 mM MgCl2. Next, 
phenol chloroform extraction was performed, followed by precipitation and 






RNA extraction solution 
Sodium Acetate 0.3 M 
EDTA   0.5 mM 




Glycerol  50g (39.7 mL) 
Potassium Chloride 100mM 
EDTA    0.2mM 
Tris pH 8.0  100mM 
Add 250ul DTT (100mM) + 50ul PMSF 
(200mM) to filtered 50ml 
 
Buffer G (Gregory 2014) 
Tris-HCl pH 7.5 20mM 
NaCl   137mM 
EDTA   1mM 
TritonX-100  1% 
Glycerol  10% 
MgCl2   1.5mM 
Add 500ul DTT (100mM) + 50ul PMSF 
(200mM) to filtered 50ml 
 
UEO RNA loading buffer 
EDTA   20mM 







Ammonium bicarbonate 10mM 
Acetonitrile   10% 
 
Trypsin Buffer  
Trypsin solution: Add 20μl of 0.1% 
trifluoracetic acid to 20μg trypsin. 
Acetonitrile/ABC solution 227μl 
Trypsin solution  3μl 
 
Tris-buffered saline (TBS) 
Tris-Cl    50mM 
NaCl    150mM 
pH 7.6 
 
Phosphate-buffered saline (PBS) 
Sodium Chloride   137mM 
Potassium Chloride  2.7mM 
Na2HPO4   100mM 




Acetone    50% 
Methanol   50% 
HCL (10M)   0.05% 
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Optimized lysis buffer K 
EDTA    20mM 
NaCl    140mM 
Tris    100mM 
SDS    5% 
 
TBE 1 X  
Tris    0.5M 
Boric acid   0.5M 
14.88g EDTA   10mM 
Add ~2.5g of NaOH pellets per litre to 
adjust pH to 8.3 
 
RNA staining solution 
Stains all stock  10% 
Formamide   10%  
Isopropanol   50% 
 
Stains-all stock: 0.1% Stains-all 
(Sigma) w:v in formamide. 
 
 
Basic sorting buffer 
PBS     1X 
EDTA    1mM 
HEPES pH 7.0   25mM 




RNA elution buffer 
NaAc pH5.2    0.3M 
EDTA     0.5mM 
SDS     0.1% 
 
Solution A 
Magnesium Chloride   32mM  
ATP    5µM  










Antibody  Catalog number   Host species     
Anti-CIRBP  Protein tech (10209-2-AP) Rabbit polyclonal 
Anti-DHX9  Protein tech (17721-1-AP) Rabbit polyclonal 
Anti-DIS3L2  Abcam (ab50848)  Rabbit polyclonal  
Anti-HADHB  LSBio (LS-B13884-50)  Rabbit polyclonal  
Anti-HnRNPA1 Millipore (05-1521)  Mouse monoclonal 
Anti-HuR  Millipore (07-468)  Rabbit polyclonal 
Anti-Lin28  Abcam (ab46020)  Rabbit polyclonal   
Anti-MSI2  Millipore (04-1069)  Rabbit monoclonal 
Anti-T7-tag-HRP Millipore (69048)  Mouse monoclonal 
GAPDH  Protein tech (10494-1-AP) Rabbit polyclonal 
 
Anti-mouse IgG Cell signalling (7076S)   





Primer  sequence   
HADHB CRISPR gRNA For CACCCGCATTCCATTTCTGCTGTC   
HADHB CRISPR gRNA Rev AAACGACAGCAGAAATGGAATGCG  
CIRBP CRISPR gRNA For CACCAGCAGGTCTTCTCCAAGTAT   
CIRBP CRISPR gRNA Rev AAACATACTTGGAGAAGACCTGCT   
Sequencing primer HADHB KO For AAAGCTGTCCAGACCAAGTC   
Sequencing primer HADHB KO Rev ATCTCACCAGCCCCAAAGAA   
Sequencing primer CIRBP KO For GGGTGGTGGTTAAGGCAAAC   
Sequencing primer CIRBP KO Rev TGGAAGGACACACATGGACA   
    
Pre-miR-329 T7 For TAATACGACTCACTATAGGTGTTCGCTTCTGGTACCGGA 
Pre-miR-329 Rev AAAAAGGTTAGCTGGGTGTG   
Pre-miR-495 T7 For TAATACGACTCACTATAGGAAAGAAGTTGCCCATGTTAT 
Pre-miR-495 Rev AAGAAGTGCACCATGTTTGT   
Pre-miR-9 T7 For TAATACGACTCACTATAGGTCTTTGGTTATCTAGCTGTA 
Pre-miR-9 Rev ACTTTCGGTTATCTAGCTTTA   
Pre-let-7a T7 For TAATACGACTCACTATAGGATGTTCTCTTCACTGTGGG 
Pre-let-7a Rev TGCAGACTTTTCTATCACGTTAGG   
    
CIRBP XbaI For TTTTCTAGAATGGCATCAGATGAAGGCAAG  
CIRBP BamHI Rev AAAGGATCCTTACTCGTTGTGTGTAGCATA  
HADHB XbaI For TTTTCTAGAATGACTACCATCTTGACT  
HADHB BamHI Rev TTTGGATCCTTTGGGGTAAGCTTCCA  
*HADHB contains two BamHI sites that where substituted out with silent mutations: 
SITE 1: For-ATCCGTCCTTCCTCACTGGA Rev-GCCATTATCTTTGGTAACTGT  
SITE 2: For-CCCGAAAGATCAGCTTTTAC Rev-TCCTGGGACACATATATAAA  
    
Lin28a XbaI For TTTCTAGAATGGGCTCCGTGTCCAACCAGCGTTTG 
Lin28a BamHI Rev_190 TTGGATCCTCAGTAGGTTGGCTTTCCCTGTGCACTAGGG 
Lin28a XbaI For_24 TTTCTAGAGCGCCGGAGGACGCGGCC  
Lin28a BamHI Rev_209 TTGGATCCTCAATTCTGTGCCTCCGGGAGCAGGGTAG 
Lin28a BamHI Rev_123 TTGGATCCTCACCGCCTCTCACTCCCAATACAGAATACTCC 
Lin28a XbaI For_123 TTTCTAGACGGCCAAAAGGAAAGAGCATGCAG AAGCG 
Lin28a BamHI Rev_74 TTGGATCCTCACACAAAGACATCCACTGGGGGG TCGAG 
Lin28a XbaI For_156 TTTCTAGACCCCAGCCCAAGAAGTGCCACTTCTG 
    
Pri-miR-329-mmu For                              AAGGTCACGTTGGGGAATTA 
Pri-miR-329-mmu Rev                             ACCACGAAGCCTCCAAGAT  
Pre-miR-329-mmu For                            TGGTACCGGAAGAGAGGTTTT 
Pre-miR-329-mmu Rev                            AGGTTAGCTGGGTGTGTTTCA                           
Pri-miR-494-mmu For                              TGCCTTTGTTTGCTTTCTGA  




Pre-miR-494-mmu For                           GGAGAGGTTGTCCGTGTTGT 
Pre-miR-494-mmu Rev                           AGGTTTCCCGTGTATGTTTCA 
Pri-miR-495-mmu For                             AGCATCCCTTCACACTCAGG  
Pri-miR-495-mmu Rev                            GAGCTCTCCAAGGTGAGATTTG 
Pre-miR-495-mmu For                            GTTGCCCATGTTATTTTTCG 
Pre-miR-495-mmu Rev                           AGTGCACCATGTTTGTTTCG   
 
ALL miRNA primers for qRT-PCR correspond to their respective mature miRNA sequence 
    





Post-transcriptional regulation of 14q32 cluster microRNAs  
Because of the vital and widespread function of miRNAs, their biogenesis is tightly 
regulated at every step of the pathway, both at the transcriptional and post-
transcriptional level266,267. Additionally, this is further complicated by the fact that 
miRNAs are frequently found in clusters, which are transcribed as a single 
polycistronic unit10–12. In humans, the largest of these clusters is cluster 14q32 (12F1 
in mice) referring to its position in the genome239. This miRNA cluster is found within 
an imprinted region of the genome that is also host to several lincRNAs and 
snoRNAs241,242. It is expressed throughout the developing embryo, and in adults its 
expression is enriched in the brain239,241,243. It has important functions in 
neurogenesis including differentiation and proliferation of neural precursors, 
dendritic development and synaptic formation243,245–248. Additionally, its 
disregulation has been associated with various diseases including cancer, 
schizophrenia and cardiovascular disorders249–257. However, this disregulation of 
14q32 miRNAs can be restricted to altered levels of specific subsets or individual 
miRNAs rather than the cluster as a whole259–265. 
The importance of this cluster in neovascularization was previously highlighted by our 
collaborators in the Netherlands251. The role of this cluster in neovascularization was 
first identified through reverse target prediction, were various genes involved in both 
angiogenesis and arteriogeniesis were probed for miRNA target sites. An enrichment 
of binding sites for 27 miRNAs in the 14q32 cluster was found in these probed genes. 
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To further study the importance of this cluster in neovascularization a microarray 
analysis was then performed in a murine hindlimb ischemia model (HLI), were ligation 
of the femoral artery was carried out to reduce blood flow to adductor muscle 
resulting in an ischemic tissue. This microarray analysis showed an upregulation of 
over half the miRNAs in the cluster after the induction of ischemia251.  
Within the group of miRNAs that were upregulated two distinct temporal patterns 
were seen; early responders first showed increased levels 24 hours after HLI whilst 
late responders did so after 72 hours. Importantly, the three distinct response 
patterns, (early-responders, late-responders and non-responders) were 
independent from the position of the miRNAs within the cluster, suggesting that the 
difference observed is due to post-transcriptional regulation of the cluster ( 
Figure 8). 
Additionally, gene-silencing oligonucleotides (GSO) were used to further study the 
effects of select 14q32 miRNAs on blood flow recovery. For this, miRNAs representing 
each temporal response pattern were selected, namely miR-329 (late responder), 
miR-494 (early responder) and miR-495 (non-responder). Mice were injected with 
GSO targeting these miRNAs and the next day HLI was induced. Blood flow recovery 
was then monitored for the following 17 days. All the treated groups, GSO-329, GSO-
494 and GSO-495 showed significantly improved blood flow recovery when 
compared to GSO-control treated mice251. Further experiments showed that GSO-
mediated silencing of all three miRNAs resulted in an increase in arteriole diameter 
and treatment with both GSO-329 and GSO-495 additionally showed an increase in 
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capillary density. This reflects the involvement of these miRNAs in the regulation of 
both arteriogeniesis and angiogenesis. Several pro-arteriogenic and pro-angiogenic 
genes were also confirmed to be upregulated after GSO-mediated silencing of miR-
329 and miR-494, including Tlr4, Vegfa, Fgrf2, Mef2a, Arf6 and Efnb2. No targets for 
miR-495 have been confirmed by GSO-495 silencing thus far, however there is still a  
large number of putative targets whose change in expression has not been analysed. 
These results indicate a direct involvement of these miRNAs in the regulation of 
neovascularization. However, this is a complex process involving multiple networks 
of regulating factors, including miRNAs, for which many details are still unknown. 
 
Figure 8 Changes in expression level of 14q32 miRNAs following ischemia. Microarray analysis 
were performed on murine adductor muscle samples to measure levels of 14q32 miRNAs after 
induction of hindlimb ischemia. These miRNAs were classified into three temporal upregulation 
patterns;  early responding (green), late responding (red) and non-responding (blue). MiRNAs 
in grey were not included in the miRNA analysis. MiRNAs in bold were used in later experiments 
to represent each of the three temporal patterns251. 
 
 
Pri-miR, pre-miR and mature miRNA levels of 14q32 miRNAs following ischemia 
To further investigate post-transcriptional regulation of miRNAs in this cluster, it was 
important to determine the levels pri-, pre- and mature miRNA levels for selected 
14q32 miRNA in an HLI model. The levels of mature and precursor miR-329, miR-494 
and miR-495 in adductor muscle following HLI were measured by qRT-PCR using 
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specific primers for each pri-miR, pre-miR and mature miRNA species (Figure 9).  
These miRNAs correspond to those previously selected to represent each distinct 
temporal pattern and whose inhibition showed a positive effect on blood flow 
recovery.   
 
Figure 9 Levels of 14q32 miRNA precursors. Levels of pri- pre- and mature miRNA levels for A) 
late-responding miR-329 B)early-responding miR-494 and C)non-responding miR-495 were 
measured by qRT-PCR using specific primers after induction of hindlimb ischemia. N=4 mice 
per timepoint. 
 
Mature miRNA levels of late-responding miR-329 showed no change 24 h after 
ischemia, but an increase in levels was observed after 72 hr. Then, there was a return 
to basal levels by day 7 post-ischemic induction. This expression pattern contrasts 
with the changes in pre-miR-329 and pri-miR-329 levels. Expression of both pri- and 
pre-miR-329 slightly decreased 24 hr after induction of HLI, but whilst the levels of 
pri-miR-329 are then maintained 72 hr after HLI induction before showing a strong 
increase after 7 days, expression of pre-miR-329 continues to decrease after 72 hr 
before showing a slight increase at day 7 (Figure 9 A). Mature miRNA levels of early-
upregulated miR-494 show an increase 24 hr after ischemia which is further 
intensified by 72 hr after induction. This trend is then reversed, with lower expression 
of mature miR-494 at day 7 relative to day 3 post ischemia, although expression is 
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still higher than base levels. Again, these changes do not correspond to the changes 
in miR-494 precursor levels. Pri-miR-494 shows a decrease from day 1 that is 
maintained throughout days 3 and 7, whereas levels of pre-miR-494 show only a 
slight decrease 24 hr post ischemia (Figure 9 B). Finally, mature miR-495 levels 
remained unchanged after induction of ischemia, despite a reduction in levels of both 
pri-miR-495 and pre-miR-495 beginning 24hr after induction of ischemia and 
continuing at later timepoints (Figure 9 C). In general, while there is a decrease in pre-
miR expression levels, increased (miR-494 and miR-329) or sustained (miR-495) 
expression levels of mature miRNAs were observed. This suggests the possibility of 
post-transcriptional regulation of these miRNAs at the processing step converting 
pre-miRs to mature miRNAs. 
Identification of novel protein factors binding 14q32 pre-miRs  
To further explore the regulation of the pre-miR to mature miRNA processing step of 
14q32 miRNAs, a serum starvation model was employed in NIH-3T3 (mouse 
fibroblast) cells. This is a system often used in the in-vitro study of ischemia and is a 
simplification of the far more complex processes that occur in ischemia in vivo. There 
are three main contributing factors driving ischemia in vivo; nutrient depravation, 
hypoxia and hypothermia. Serum-starvation mimics the effects of nutrient 
depravation. Additionally, in whole muscle tissue there is a coexistence of multiple 
cell-types, one of which is fibroblasts. Serum-starvation of NIH-3T3 fibroblasts 
therefore allows to study effects on miRNA regulation that are also expected to occur 
in an in vivo ischemic model. Using this simplified model allows for controlled 
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conditions that are reproducible and production of sufficient material for 
experiments carried out.  
Using this starvation model, protein factors capable of differentially binding to the 
upregulated pre-miR-329 and unresponsive pre-miR-495 were sought. To identify 
interacting RBPs, RNA pulldown assays followed by stable isotope labelling of amino 
acids (SILAC)-mass spectrometry (RP-SMS) were carried out. SILAC was carried out 
utilizing the incorporation into NIH-3T3 cells of non-radioactive ‘heavy’ [Arg13]/[Lys13] 
isotopes which can be distinguished from naturally occurring ‘light’ [Arg12]/[Lys12] 
isotopes, allowing for the quantification of relative abundance of proteins using mass 
spectrometry. Here, light NIH-3T3 cells were grown in media fully complemented 
with 10% fetal bovine serum (non-starved) while heavy cells were grown in media 
complemented with 0.5% fetal bovine serum (starved). Total extracts of both heavy 
and light cells were then combined and incubated with agarose beads chemically 
coupled to either pre-miR-329 or pre-miR-495 (Figure 10). Proteins that showed 
differential binding upon starvation represent putative factors for post-






Figure 10 RNA pulldown followed by SILAC-mass spectrometry. Diagram representing 
methodology used to identify protein factors binding to 14q32 pre-miRs, pre-miR-329 and 
pre-miR-495 in a cellular starvation model. 
 
A total of 104 and 111 proteins showed decreased or increased binding of at least 
50%, respectively, to either pre-miR-329 or pre-miR-495 upon starvation (Figure 11). 
Of these proteins, only a subset showed differential binding upon starvation to both 
pre-miRs, with 20 proteins showing decreased binding and 35 proteins showing 
increased binding to both pre-miR-329 and pre-miR-495. These binding patterns 
indicate the potential for pre-miR-329 and pre-miR-495 to be co-regulated by certain 
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protein factors whilst possibly also being individually regulated by another set of 
proteins. 
Validation of proteins showing differential binding to pre-miRs upon starvation 
To continue gaining insight into the regulation of these pre-miRs, eight proteins 
identified by RP-SMS were selected for validation by RNA pulldown followed by 
western Blot analysis. The focus on these eight proteins was based on them showing 
differential binding upon starvation to either pre-miR-329, pre-miR-495 or both 
miRNAs as well as them having been reported to bind RNA in genome wide studies 
without having established roles in miRNA biogenesis. The selected proteins are 
summarized in Table 1. 
For this experiment NIH-3T3 cells were grown in either starved or non-starved 
conditions and total cell extracts were then individually incubated with beads 
coupled to pre-miR-329 or pre-miR-495.  Proteins that bound to the coupled beads 
were then analysed by western blot using  specific antibodies against the selected 
Figure 11 Proteins showing decreased and increased binding upon serum starvation. Proteins 
identified by RNA pulldown followed by SILAC-mass spectrometry as binding pre-miR-329, pre-
miR-495 or both pre-miRs differentially upon starvation. 
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proteins. In all experiments, RNA-helicase DHX9, an abundant protein with high 
RNA-binding affinity,  was used as a  positive RNA-binding control.
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                   Protein name Canonical roles 









protein 4 (CKAP4) 
Endoplasmic reticulum (ER) transmembrane protein 
which helps maintain ER structure by anchoring rough 
ER to microtubules386. 




Cold-induced RNA binding 
protein (CIRBP) 
Cellular stress response protein which binds and 
stabilizes specific mRNAs under stress 
conditions387,388.  





protein 15 (RBM15) 
Various functions; involved in regulation of 
alternative splicing389, adaptor protein within the 
methyltransferase writer complex390 and is required 
for XIST-mediated silencing391. 
Increased binding to pre-
miR-329 and decreased 






Nuclear protein that functions as part of various 
transcriptional repressor and activator complexes392. 
Only binds to pre-miR-329 




subunit beta (HADHB) 
One of two subunits of mitochondrial trifunctional 
protein, which catalyses the last three steps of β-fatty 
acid oxidation. This subunit contains the 3-ketoacyl-
coA-thiolase activity393. 






 Table 1 Selected proteins for validation following RP-SMS 
Protein disulphide-
isomerase (P4HB/PDI) 
Multifunctional protein that catalyses disulphide 
bond formation and isomerization and additionally 
functions as a chaperone394. 




RNA binding protein 28 
(RBM28) 
Component of the spliceosomal ribonucleoprotein 
complexes395. 
Only binds to pre-miR-329 
with decreased binding 
upon starvation 
1.897 --- 
Pyruvate kinase PKM 
(PKM1) 
Glycolytic enzyme that catalyses the conversion of 
phosphoenolpyruvate and ADP into ATP and 
pyruvate396. 






The binding of two of the selected proteins, Cold-Induced RNA Binding Protein 
(CIRBP) and Hydroxyacyl-CoA-dehydrogenase trifunctional enzyme subunit beta 
(HADHB), to pre-miR-329 and pre-miR-495 was successfully validated by RNA 
pulldown followed by western Blot (Figure 12). Unfortunately, validation of the other 
selected proteins was unsuccessful; no specific signal was detected either in the total 
extract input or the pulled down fraction using antibodies against CKAP4, PDI or PKMI 
whilst the signal for RBM28 was very faint in the input and virtually undetectable in 
the pulled down fractions (data not shown). A signal for RBM15 could be detected in 
the input but was not detected in the pulled down proteins, similarly TBLR1 was also 
detected in the input but the signal in the pulldown fractions was inconsistent and 
did not correspond to the changes in binding expected from RP-SMS. Further 
experiments therefore focused on CIRBP and HADHB, however it is important to note 
that the lack of validation does not rule out the possibility that other proteins 
detected by RP-SMS could be binding to 14q32 miRNA precursors and regulating their 
processing.  
HADHB is one of two subunits that constitute the mitochondrial trifunctional protein 
(MTP), along with HADHA. The MTP is a multienzyme complex found in the inner 
mitochondrial membrane that catalyses the last three steps of the β-oxidation of 
fatty acids, the metabolic pathway that breaks down fatty acids to produce 
energy397,398. This complex is an octamer consisting of four α-subunits (HADHA) which 
contain 2,3-enoyl-coA hydratase and 3-hydroxyacyl-coA dehydrogenase activity and 
four β-subunits (HADHB) which exhibits 3-ketoacyl-coA thiolase activity399. HADHB 
exhibits a classical thiolase fold which consists of two domains comprised of a 5-
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stranded β-sheet sandwiched between two α-helixes on either side and a third loop 
domain, it assembles into a tight homodimer399,400.  
Aside from its canonical role in β-oxidation of fatty acids, HADHB has been shown to 
bind to bind to the 3’UTR of renin mRNA (REN), destabilizing it375,401. In those studies, 
HADHB was shown to be present in the nucleus and cytoplasm in addition to is 
expected mitochondrial localization375,401. 
CIRBP is a stress-response protein originally identified as being upregulated in 
response to mild cold-shock402, but whose expression has since been shown to 
increase in response to various stresses including UV radiation403 and hypoxia404. 
Upregulation of CIRBP is regulated at various stages including transcription, 
translation and splicing405–407. CIRBP consists of two domains, an N-terminal RNA 
recognition motif (RMM) and a C-terminal glycine-rich domain (RGG)356. Under 
normal conditions CIRBP is a nuclear protein, however upon stress it is translocated 
to the cytoplasm in a mechanism mediated by methylation of its glycine rich 
domain408,409. CIRBP is regulated by an additional post-transcriptional modification, 
phosphorylation by protein kinase GSK3β, which was shown to increase the RNA 
binding capacity of CIRBP by 2-fold410.  
CIRBP mediates the post-transcriptional upregulation of specific stress-induced 
targets involved in various cellular pathways including proliferation411, translation 
regulation412, survival413,414 and DNA repair415. Upon stress, CIRBP binds to the 3’UTR 
of target mRNAs, stabilizing them and consequently leading to their enhanced 
translation412,415,416. Additionally, CIRBP was shown to increase rate of translation at 
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the initiation stage410 and influence gene expression through poly-adenylation of its 
targets417. Countering its positive regulatory functions, upon stress CIRBP can migrate 
to stress granules were it functions as a translational repressor408. Additionally CIRBP 
can directly interact with protein kinase and cell-cycle regulator DYRK1B, promoting 
cell-cycle progression418,419. The multiple roles and modes of regulation of CIRBP 
allow it to be a versatile protein that can respond in multiple ways to a variety of 
cellular stresses.  
Western blot analysis of RNA pulldowns with starved and non-starved 3T3-NIH cells 
generally showed an increase in both HADHB and CIRBP binding to pre-miR-329 and 
pre-miR-495 upon starvation (Figure 12-13). This increase was particularly evident in 
the binding of HADHB to pre-miR-329, where HADHB displayed little to no binding 
under non-starvation conditions but showed an increase upon starvation. Similarly, 
HADHB also exhibited increased binding to pre-miR-495 upon starvation, however 
this increase was more modest and, in contrast to pre-miR-329, some binding is also 







Figure 12 Validation of CIRBP and HADHB binding to 14q32 pre-miRs. Western blot analysis 
following  RNA pulldown. Total extracts from cells grown in fully-complemented media (lanes 
1-4) or serum-free media (lanes 5-8) were incubated with agarose beads coupled to 
pre-miR-329 (lanes 3,7) or pre-miR-495 (lanes 4,8). Bound protein fractions were recovered, 
run on a gel, transferred and blotted against antibodies indicated in the left side of the panel. 
DHX9 serves as a binding control. Lanes 1 and 5 correspond to the loaded extract and lanes 2 





Figure 13 Quantification of HADHB and CIRBP binding in RNA pulldown assays. Densitometry 
analysis of western blot showing HADHB (A) and CIRBP (B) binding to pre-miR-329 and 
pre-miR -495 in RNA pulldown assays. These results represent three independent 




Expression of HADHB and CIRBP in vivo 
After validating binding of CIRBP and HADHB to pre-miR-329 and pre-miR-495 in RNA 
pulldown assays it was of interest to explore the changes in levels of these proteins 
in vivo, looking at the expression of both HADHB and CIRBP in adductor muscle after 
induction of HLI. Expression of both HADHB and CIRBP in adductor muscle of mice 
one day after ischemia was confirmed via immunohistochemistry, both proteins were 
found dispersed throughout the cells (Figure 14). Localization of both proteins in the 
cytoplasm is consistent with their potential to bind pre-miRs in vivo.  
Expression levels of HADHB and CIRBP mRNAs were obtained from microarray 
analysis of adductor muscle tissue at several timepoints after induction of HLI. An 
increase in mRNA levels of CIRBP was observed from 24 hours after induction of 
ischemia which continued until 72 hours post-ischemia were CIRBP mRNA reached 
maximum expression. HADHB mRNA expression showed an increase only after 72 
Figure 14 Presence of HADHB and CIRBP in adductor muscle following induction of ischemia. 
Immunochemical staining of adductor muscle tissue samples of mice one day after induction of 
HLI. Antibodies against CIRBP and HADHB were used, as indicated in the upper left corner of the 
panels. Antibody staining is seen in a brown hue, whilst nuclei are observed in blue. 
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hours before returning to base levels by day 7 post-ischemia. This increase at day 3 
corresponds to the time point were largest changes in levels of mature miR-329 as 
well as both pre-miR-329 and pre-miR-495 were observed. To confirm that changes 
in mRNA levels corresponded to an increase in protein levels, western blot analyses 
were carried out using total protein extracts of adductor muscle tissue at 24 and 72 
hours after ischemia (Figure 15). An increase in HADHB protein levels after induction 
of ischemia was observed at day 3 after HLI induction, but not at day 1, this 
corresponds to the change observed in mRNA levels. Unfortunately, CIRBP protein 
levels could not be detected due to a low signal.  
 
Figure 15 Changes in mRNA levels of CIRBP and HADHB following induction of ischemia. Data for 
the levels of CIRBP and HADHB was obtained from microarray analysis at various timepoints 






Figure 16 Levels of HADHB protein in adductor muscle following induction of ischemia. Total 
protein was extracted from the adductor muscle samples from mice at days 0, 1 and 3 after 
induction of hindlimb ischemia. For each time point samples from the right (R) un-ligated paw 
and left (L) ligated paw were compared. Total protein was analysed by western blot (A) with 
antibodies against HADHB and tubulin as a protein loading control. Densitometry analysis of 
western blot signal was then performed (B) with HADHB protein levels normalized to tubulin. 
Ratios of the ligated vs un-ligated paw are presented. One-sample T-test was used to analyse 
the results, *=p<0.05. 
92 
 
Overexpression of HADHB and CIRBP in cellular cultures 
After the potential for physiological relevance in vivo was established, the next 
question concerned the effects of altering the levels of HADHB and CIRBP proteins in 
NIH-3T3 cells. Initially, HADHB and CIRBP proteins were cloned into an expression 
vector containing a T7-tag and subsequently overexpressed in NIH-3T3 cells (Figure 
17). Levels of mature miR-329 and miR-495 were then measured by qRT-PCR and 
compared to mock-transfected cells. MiR-423, a widely expressed and stable miRNA 
not found in in cluster 14q32 was included as a control420–423. Overexpression of 






Figure 17 Western Blot showing overexpression of HADHB and CIRBP. Total protein extracts of 
cells transfected with either T7-CIRBP or T7-HADHB expression vectors in increasing 
concentrations (as indicated above the panels) and mock-transfected cells were blotted 









Figure 18 Changes in levels of miR-329 and miR-495 upon overexpression of CIRBP and HADHB. 
CIRBP and HADHB were transfected into NIH-3T3 cells. Levels of miR-329 and miR-495 were 
measured by qRT-PCR and compared in mock transfected cells and CIRBP/HADHB transfected 
cells. Measurements were normalized to miR-16, miR-423 was used as a control miRNA. One-
sample T-test showed no significant difference between mock transfected and CIRBP/HADHB 
transfected cells.   
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Generation of HADHB KO cell lines by CRISPR/CAS9 
A more comprehensive approach to analysing changes in miR-329 and miR-495 levels 
in response to changes in expression levels of RNA binding protein HADHB and CIRBP 
involved the generation of knock-out (KO) cell lines using the CRISPR/Cas9 system 
(Figure 19). To do this one guide RNA targeting exon 1 of CIRBP and exon 3 of HADHB 
were selected and cloned into a spCas9 nuclease expressing vector which also 
contains a GFP marker (px458). NIH-3T3 cells were then transfected with these 
expression plasmids and after 24 hours positively transfected cells were individually 
selected by fluorescence-activated cell sorting (FACS) flow cytometry, utilising the 
fluorescent signal from the GFP marker. Selected cells were grown into individual 
colonies which were screened for mutations in HADHB or CIRBP genes by amplifying 
the region surrounding the target sequence and inserting it into a vector with regions 
aligning to sequencing primers. Ten 96-well plates were sorted for each targeted 
protein, however only around 40 wells grew into single colonies that could be 
screened. Finally, depletion of proteins in colonies with identified DNA deletions was 
confirmed by western blot (Figure 19).  
Whilst some of the colonies screened for deletions in CIRBP showed mutations in one 
copy of the gene, no colonies with complete depletion of CIRBP were generated. Two 
individual clones with total depletion of the HADHB gene were successfully 
generated, these cells were labelled AQ and Z as reference. The region surrounding 
the targeted sequence in the HADHB gene was amplified and sequenced, and for each 
of these clones two distinct mutations were identified (Figure 20). All the mutations 
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identified for both clones either correspond to frame-shift mutations or span an 
intron-exon junction. To confirm these mutations translated to a complete depletion 
of protein levels total protein extract of colonies AQ and Z were compared in a 
western blot against decreasing amounts of NIH-3T3 protein extracts (Figure 21). No 
signal was detected in either of the HADHB KO clones when probed with HADHB 
antibodies. 
  
Figure 19 Generation of knock-out cell lines using CRISPR/Cas9 system. Schematic 
representation of methodology used in the generation of HADHB and CIRBP knockout cells. 
3T3-NIH cells were transfected with plasmid px458, a Cas9 expressing vector with a GFP marker 
cassette into which guide RNAs where integrated. After 24 hours positively transfected cells 
were sorted into individual colonies by flow cytometry. Genomic DNA was extracted from all 
colonies that grew,  and the region surrounding the guide RNA target was amplified. These 
amplification products were extracted and cloned into a sequencing vector. Protein levels were 







Figure 21 Depletion of HADHB protein levels in knockout clones. Western blot analysis of HADHB 
levels in total protein extracts of knockout clones AQ and Z. Extracts were run alongside 
decreasing quantities of NIH-3T3 WT protein extract. Housekeeping gene GAPDH is used as a 
loading control. 
Figure 20 Sequence alignment of CRISPR-Cas9 target region in HADHB knockout clones. 
Alignment of the sequences corresponding to the region surrounding the CRISPR-Cas9 target 
sequence from genomic DNA of HADHB KO clones AQ and Z. All sequences correspond to either 
a frame shift mutation or an exon-intron junction 
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Levels of mature miR-329 and miR-495 in HADHB KO cell-lines 
Once depletion of HADHB had been confirmed, the impact of this depletion on the 
levels of mature miR-329 and miR-495 was examined. For this, qRT-PCR analysis was 
used to compare the levels of these miRNAs in the WT an KO cell lines. In both HADHB 
KO cell lines, a decrease of over 80% compared to WT NIH-3T3 cells was observed for 
both mature miR-329 and miR-495 (Figure 22). As a control, levels of mature miR-423 
were also measured in both WT and KO cells. Importantly, no changes were observed 
in levels of miR-423, this is an indication that the effects of HADHB depletion are 
specific and not due to a global reduction in miRNA biogenesis.  
Levels of pre-miR-329 and pre-miR-495 in KO-cell lines 
To determine if the change in mature miR-329 and miR-495 levels was in fact due to 
changes in post-transcriptional regulation of the pre-miR to mature miRNA 
processing step it was important to look at the levels of pre-miR-329 and pre-miR-495 
in the KO cell lines. Levels of pre-miR-329, pre-miR-495 and pre-miR-423 were 
analysed in HADHB clones AQ and Z (Figure 23). Unlike mature miRNA levels, 
pre-miR-329 and pre-miR-495 levels remained constant. This corroborates that there 
is in fact a change in mature pre-miR-329 and pre-miR-495 processing as similar levels 
of pre-miRs result in much lower levels of mature miRNAs. These results are 
consistent with in vivo observations, where an increase in HADHB levels correlates 
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with an increase in miR-329 levels and a steady level of miR-495 levels despite a 
decrease in pre-miR-329 and pre-miR-495. 
  
Figure 22 Levels of mature miR-329 and miR-495 in HADHB knockout clones. Levels of mature 
miR-329 and miR-495 were measured in WT and KO cell lines in the two HADHB clones; AQ 
(A) and Z (B). All measurements were normalized against miR-16 and miR-423 was used as a 








Following these results, it was attempted to see whether the expression of mature 
miR-329 and miR-495 in HADHB KO cell lines could be restored upon the re-
Figure 23 Levels of pre-miR-329 and pre-miR-495 in HADHB knockout clones. Levels of pre-miR-
329 and pre-miR-495 were measured in WT and KO cell lines in the two HADHB clones; AQ (A) 
and Z (B). All measurements were normalized against pre-miR-16 and pre-miR-423 was used 

















































expression of HADHB. For this, T7-tagged HADHB was transiently expressed in HADHB 
KO cells by transfection of an expression vector. Mature miRNA levels were measured 
48 hours after transfection, however no effect on the levels of mature miR-329 and 
miR-495 was observed (Figure 24). Similarly, no effects were seen at 24 and 72 hours 
(Data not shown). It is possible that this time frame is not sufficient for recovery of 
HADHB activity and that longer expression times are needed for the rescue of mature 
miRNA levels. Other possibilities include that exogenous HADHB is not undergoing 
post-translational modifications necessary for it to carry out its RNA-binding activities 
or that it’s localization within the cell is not reflecting that of the endogenous protein. 




Figure 24 Mature miR-329 and miR-495 levels after re-expression of HADHB in KO cell lines. 
HADHB was transiently expressed in HADHB KO cell lines. Mature miRNA levels were 
measured 48 hours after transfection and compared to the levels of WT and HADHB KO cell 




Despite miRNAs of the 14q32 cluster being dysregulated in multiple pathologies, 
knowledge regarding post-transcriptional regulation of the cluster is lacking. Previous 
experiments identified the upregulation of over half the miRNAs in this cluster upon 
induction of hindlimb ischemia251. This upregulation occurred in three distinct 
temporal patterns that were independent of the position of the miRNAs within the 
cluster. The different  changes in levels of individual miRNAs despite the transcription 
of the cluster as a single polycistronic unit suggested post-transcriptional regulation 
during the biogenesis of 14q32 miRNAs. Further analysis indicated the processing 
step from pre-miR to mature miRNA of selected miRNAs was likely be subjected to 
regulation by unknown factors. 
Here,  identification of these protein factors was sought through RP-SMS, focusing on 
the regulation of pre-miR-329 and pre-miR-495, precursors of two miRNAs from the 
14q32 cluster that are important in the response to ischemia. In this study we used 
serum-starvation to identify factors binding to and regulating pre-miR-329 and pre-
miR-495 processing in NIH-3T3 cells. Because in vivo ischemia is a much more 
complex process in the future it would be important to also study the effects of 
hypothermia and hypoxia in both this cell line and other cell types that are present in 
whole muscle tissue. 
In the serum-starvation model used here, HADHB and CIRBP were identified as  
binding differentially to pre-miR-329 and pre-miR-495, with both proteins showing 
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increased binding to these pre-miRs upon serum starvation (Figure 12-13). 
Furthermore, deletion of HADHB in NIH-3T3 cells resulted in a reduction of over 80% 
in the levels of mature miR-329 and miR-495 but did not alter the levels of 
pre-miR-329 and pre-miR-495 (Figure 22-23). Taken together this suggests that these 
proteins have a role in regulating the processing of pre-miR-329 and pre-miR-495. A 
decrease in pre-miRNA processing often leads to accumulation of pre-miRNA as well 
as a reduction in mature miRNA levels, however this was not observed in this study. 
This could be due to rapid turnover of unprocessed pre-miRNA species, but further 
exploration of transcription and degradation rates would be necessary to corroborate 
this. 
Although a strong reduction in miRNA levels was seen upon deletion of HADHB, 
overexpression of HADHB and CIRBP had no effect on mature miR-329 and miR-495. 
This could be due to various reasons. For example, it is possible that endogenous 
levels of these proteins are already sufficient for maximizing their interaction to pre-
miR-329 and pre-miR-495 or that these proteins might require interaction with other 
protein factors that are limiting the upregulation of these miRNAs. Another possibility 
is that endogenous proteins undergo post-transcriptional modifications necessary for 
their binding to pre-miR-329 and pre-miR-495 that are lacking from overexpressed 
HADHB and CIRBP. 
CIRBP and HADHB were part of a large group of proteins that were identified to bind 
differentially to these pre-miRs upon starvation (Figure 11), however they were the 
only proteins successfully validated in this study via RNA pulldown followed by 
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western Blot. This prompted them to be the focus of subsequent studies, but this 
does not invalidate the initial SILAC-mass spectrometry findings and the information 
obtained from this experiment can be used in the future as potential research 
avenues. 
Importantly, both HADHB and CIRBP were shown to be expressed in adductor muscle 
in vivo, dispersed throughout the cell. Specifically, both proteins were present in 
cytoplasm, where Dicer cleaves pre-miRs into miRNA duplexes meaning that the 
spatial context of these proteins would permit them to bind to pre-miRs (Figure 14). 
Because immunohistochemistry was only carried out at one time point after ischemia 
it is not possible to ascertain whether these proteins showed a change in localization 
after ischemic induction, which would be interesting to explore further in the future.   
Additionally, the mRNA levels of both HADHB and CIRBP show an increase upon 
induction of HLI which reaches a maximum at Day 3 (Figure 15). In the case of HADHB, 
the same was observed at the protein level (Figure 16). Again, this is temporally 
consistent with the largest increase in mature miR-329 levels and simultaneous 
decrease in pre-miR-329 and pre-miR-495 levels.  
Understanding how the upregulation of these proteins is mediated in response of 
ischemia is of interest moving forward. Expression of CIRBP has previously been 
reported to increase in response to hypoxia404,  one of the major consequences of 
ischemia. Interestingly, this upregulation is independent of hypoxia inducible factor 
1 (HIF1), the main regulator of the ischemic response404,424. Several mechanisms have 
been proposed to mediate increased CIRBP expression in response to stress, 
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including more efficient splicing of CIRBP pre-mRNA in response to mild hypothermia 
and changes in the abundance of three major CIRBP transcripts in response to 
temperature, each with different transcriptional start sites and varying 5’ UTR 
lengths406,407. 
A further study identified an element in the CIRBP 5’UTR that functions as a mild-cold 
response element (MCER) and which can be bound by transcription factor Sp1, whose 
levels in the nucleus were increased at 32 °C compared to 37 °C405. Sp1 is a 
transcriptional factor that regulates the expression of thousands of genes. It is 
considered to be a basal transcriptional factor and is ubiquitously expressed425. 
However, interaction with a wide repertoire of transcriptional regulators as well as 
modulation by post-transcriptional modifications means that the activity of Sp1 can 
be altered in response to various cellular contexts425,426. Sp1 has been shown to be 
upregulated in response to ischemia427 and the activation of various genes under 
conditions of serum-starvation and hypoxia has been shown to be dependent on 
Sp1428–433. Interestingly, HADHB is also under the transcriptional control of Sp1398. 
Taken together, it’s tempting to speculate a potential role of Sp1 in mediating the 
increase of CIRBP and HADHB levels in response to hypoxia and in the future, this 
would be interesting to explore further.  
Apart from the increase in protein levels, cytoplasmic translocation of CIRBP and 
HADHB is likely to be an important factor in them binding pre-miR-329 and pre-
miR-495, as it is in the cytoplasm where Dicer mediates the processing of pre-miRs 
into miRNA duplexes. HADHB is a mitochondrial protein, where it carries out its 
105 
 
canonical role in fatty-acid oxidation. However, both here and in other studies 
presence of HADHB in the cytoplasm has been reported375,401; the mechanisms 
regulating HADHB localization are unknown and would be interesting to study moving 
forward. CIRBP is considered a nuclear protein under normal conditions, but has been 
shown to translocate to cytoplasm upon a variety of stresses408,415,434. Nuclear export 
is dependent on methylation of arginine residues in the RGG domain of CIRBP, which 
seem to be dependent on protein arginine methyl-transferase 1 (PRMT1)408,435. 
Interestingly, PRMT1 levels have been shown to increase upon the induction of 
ischemia436. In the future it would be interesting to explore the effects of PRMT 
inhibitors on the localization of CIRBP, and whether this has a subsequent effect on 
levels of 14q32 miRNAs.  
Methylation is not the only post-translational modification known to affect the 
activity of CIRBP, phosphorylation of the RGG domain by Glycogen synthase kinase 3 
β (GSK3β) is able to increase the RNA-binding activity of CIRBP twofold410. Activity of 
GSK3β can vary in response to hypoxia, with both inhibition and activation being 
observed in different cell types437–439. The activation of GSK3β presents another 
possible factor affecting the regulation of CIRBP in ischemia and understanding its 
potential effects could open up various potential therapeutic targets in the future. 
CIRBP had an evolutionarily conserved homolog, RNA-binding motif protein 3 
(RBM3)440. Like CIRBP, RBM3 is upregulated in response to a variety of stresses and 
is involved in the stabilization and increased translation of mRNAs in multiple cellular 
pathways. Whilst both proteins are widely expressed their localization can vary with 
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differences at tissue and cell-type level as well as subcellular localization. For 
example, in testis CIRBP is predominantly expressed in germ cells whilst RBM3 is 
found in Sertoli cells and whilst under normal conditions both proteins show a mostly 
nuclear localization RBM3 shows enhanced cytoplasmic presence in the brain whilst 
CIRBP shows greater cytoplasmic localization in spermatids440. Information on how 
upregulation of RBM3 is achieved is lacking in comparison to CIRBP.  
Interestingly, RBM3 has been associated with regulation of miRNA biogenesis313,441. 
In one study, miRNA arrays showed that 60% of miRNAs detectable in a neural cell 
line were downregulated upon knockdown of RBM3 whilst there were no changes in 
pri-miR levels, indicating the involvement of RBM3 in post-transcriptional regulation 
of miRNA biogenesis. RBM3 was found to associate with pre-miRs and promote their 
processing by dicer313. Considering their homology, this suggests CIRBP could be 
playing an equivalent role. In this study miR-329 and miR-495 were not amongst the 
RBM3-upregulated miRNAs, this could be due to the subtle differences in RBM3 and 
CIRBP structure or more likely because of the difference in cell type and cellular 
context. It would be interesting to further explore the relationship between CIRBP 
and RBM3 regulation of miRNA biogenesis,  whether they share miRNA targets and 
whether they indeed employ the same mechanism. A second study found an opposite 
effect of RBM3 levels where RBM3 knockdown increased the levels of miR-142 and 
miR-143. These miRNAs are upregulated in fever-like temperatures (40 °C) were their 
expression shows opposite patterns to RBM3 levels441. This shows that RBM3 has the 
potential to decrease miRNA levels, and it would be of interest to explore the 
possibility of negative regulation on miRNA levels by CIRBP. 
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HADHB is one of two subunits that form the mitochondrial trifunctional protein, 
responsible for the oxidation of fatty acids, the other subunit being HADHA. 
Interestingly, HADHA was identified in a study as interacting partner of Dicer442.  In 
the study, immunoprecipitations were carried out to identify novel Dicer interacting 
partners, and along with TRBP and PACT, HADHA was pulled down. Furthermore, 
over-expression of HADHA resulted in lower levels of specific pre-miRNAs ,including 
pre-miR-126, accompanied by an increase in mature miR-126. Knockdown 
experiments with HADHA specific siRNAs showed the opposite effect; higher levels 
of pre-miR-126 and a 50% reduction in miR-126 levels442. These results suggest that 
the association of HADHA with Dicer enhances processing of specific pre-miR to 
mature miRNAs. This increase in pre-miR to mature processing is equivalent to the 
role proposed for HADHB in this study. HADHA has not been found to associate with 
RNA, and no mechanism has been proposed for its role in regulating miRNA 
biogenesis. Being interacting partners, it is likely that HADHB would be able to bind 
Dicer-associated HADHA. This would provide a mechanism in which the interaction 
of HADHB and HADHA brings pre-miRs into proximity with Dicer, potentially 
enhancing their processing. It is something that should be explored further, and it 
would be helpful to understand whether silencing of HADHA abolishes the regulatory 
effects of HADHB on miRNA biogenesis and vice versa.  
Another potential path for exploring the role of HADHB in miRNA regulation is the 
effects of its inhibitor, trimetazidine. Trimetazidine, an anti-anginal drug with 
cardioprotective effects during ischemia, and an inhibitor of HADHB443,444. The 
mechanism behind its cardioprotective functions was first suggested to be a 
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metabolic shift from fatty-acid oxidation to glucose oxidation443,445, however this has 
been disputed with a study finding it had no effect on the turnover of specific 
substrates or inhibition of β-fatty acid oxidation446. Additionally, new side effects 
have recently been reported445. Because of controversial results on the effect of 
trimetazidine on HADHB function, exploring the effect of trimetazidine on miRNA 
biogenesis would be an interesting avenue to explore and could even lend insight into 
potential side effects of the drug. 
While in this study CIRBP and HADHB were identified binding to pre-miR-329 and 
pre-miR-495, their roles in the regulation of miRNA biogenesis are likely to extend to 
other miRNAs both part of the 14q32 cluster and outside of it. It is important to 
understand how far reaching the regulatory roles of CIRBP and HADHB are; small RNA 
sequencing of KO and WT cell lines would be a key step in identifying the extent of 
their effects on miRNA levels and would be a good next step moving forward.  Several 
miRNAs outside of the 14q32 cluster are responsive to hypoxic/ischemic conditions, 
including miR-21, miR-210, miR-424, miR-100, miR-15/16 and miR-132/212447–449. 
Additionally, various miRNAs including some hypoxic-responsive miRNAs have shown 
anti-angiogenic effects, these include miR-15/16, miR-21, miR-100, miR-34a, miR-
124, miR-29, miR-206, miR-26 and members of the miR-17~92a cluster447,448,450. 
There is likely to be several mechanisms regulating the changes in expression of these 




Beyond this, it is possible that CIRBP and HADHB can influence miRNA levels in other 
cellular contexts. Whilst changes in expression or localization of HADHB in response 
to external stimuli aren’t well documented, it is known that CIRBP is responsive to a 
variety of cellular stresses and analysing how these changes reflect in miRNA profiles 
is an interesting avenue to explore. Recently, CIRBP has begun to emerge as a 
potential oncogene451,452. It was found overexpressed in several human tumours, 
including 33% of colon tumours and 45% of breast tumours452. CIRBP can influence 
multiple aspects of cancer, leading to increased proliferation, decreased apoptosis, 
avoidance of senescence, downregulation of p53 and upregulation of telomerase 
activity. It is a potential marker for poor prognosis in adenomas and its 
downregulation enhances chemeosensitivity451. Whilst it is believed that many of 
these effects are governed through CIRBP targeting cancer-associated mRNAs the 
possibility of CIRBP-dependent dysregulation of miRNA levels could also be at play, 
considering that dysregulation of miRNAs in cancer is common. This is an interesting 
scenario in which to explore the role of CIRBP in miRNA biogenesis. 
The identification of CIRBP and HADHB in this study is an important first step in 
understanding the regulation of 14q32 miRNAs in the response to ischemia. The 
experimental evidence strongly suggests that these proteins are playing a key role in 
the processing of pre-miR-329 and pre-miR-495 into mature miR-329 and mature 
miR-495. Considering the importance of these miRNAs in the ischemic response, 
understanding their regulation could allow to better influence their levels following 
ischemia and improving therapeutic effects on neovascularization. However, it is 
possible that the roles of CIRBP and HADHB in regulating miRNA biogenesis extend 
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beyond both this cluster and particular cellular context. It is  exciting to explore the 
full extent of their regulatory potential on miRNA biogenesis.  Accompanying this, it 
is of great importance moving forward to elucidate the mechanisms through which 
these proteins are exerting their effects on miRNA processing, and how these are 




Lin28a regulation of miRNAs during neurogenesis 
The regulation of let-7 by Lin28a is the best studied example of post-transcriptional 
regulation of miRNAs. Let-7 was one of the first miRNAs described, initially identified 
in a screen for heterochronic genes in C. elegans where it was found expressed in late 
larval and adult stages, but not early larval stages187. It was then shown to be highly 
conserved across animal species, conserving its temporal expression pattern9. 
Various miRNAs containing the same let-7 seed sequence are often present in a 
genome and are referred to as the let-7 family of miRNAs. To distinguish between 
members of the family a letter and/or number is used. Letters indicate differences in 
the mature miRNA sequence, outside of the seed, whereas numbers indicate 
identical mature miRNA sequences originating from different sites in the genome. In 
mouse and human 9 mature let-7 sequences originating from 12 transcripts are 
found; let-7-a1, -a2, -a3 (human), -b, -c(1), -c2 (mouse), -d, -e, f1, -f2, -g, -i and miR-
98453.  
Let-7 has important conserved roles in development. In C. elegans it is necessary for 
transition from the last larval stage into the adult stage and it is similarly important 
in the juvenile-to-adult transition in Drosophila8,454. In Dgcr8 deficient mouse ES cells, 
let-7 was able to supress self-renewal by repressing pluripotency factors including 
Lin28, Sall4 and N-Myc104. Let-7 was also found to be a barrier in reprogramming of 
induced pluripotent stem cells (iPSC). A key factor in this impediment was let-7 
repression of LIN41/TRIM71 which in turn regulates a broad range of differentiation 
factors455. Let-7 also has specific roles in neurogenesis, promoting neural stem cell 
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proliferation and differentiation through repression of TLX1, an orphan nuclear 
receptor that is essential in regulating neural stem cell self-renewal456,457. 
Additionally, let-7 targets IGF2-mRNA binding protein 1 (IMP1), a protein widespread 
in fetal tissues, but not adult tissues, which can bind to mRNAs of various self-renewal 
genes leading to their increased expression. Repression of IMP1 by let-7 promotes a 
developmental switch from highly proliferative neural stem cells to more quiescent 
adult stem cells458.  
Mature let-7 is absent in mouse and human embryonic stem cells but increases in 
expression upon differentiation. In contrast, pri-let-7 levels are present in similar 
amounts in undifferentiated and differentiated cells, indicating let-7 is under 
negative post-transcriptional regulation in undifferentiated cells320,321,459. The protein 
responsible for inhibiting let-7 processing in undifferentiated cells is pluripotency 
factor Lin28100–103. Lin28 was first characterized in C. elegans as an important 
regulator of developmental timing.  It is composed of two RNA-binding domains; a 
cold-shock domain and a pair of CCHC-type zinc fingers460. Lin28 is conserved in 
mammals where two homologs of Lin28, Lin28a and Lin28b are present324. It is 
abundant in embryonic tissues, embryonic cell lines and human and mouse ES cells 
after which it is progressively lost during differentiation461–463. Furthermore, Lin28a 
was one of four factors sufficient for reprogramming of induced pluripotent stem 
cells, along with Oct4, Sox2 and Nanog322. 
Lin28a has let-7 independent roles, regulating translation of a specific subset of 
mRNAs through binding to conserved motifs and structures in their 3’ UTR464–466. 
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However, the pluripotency effects of Lin28 are mostly mediated through inhibition of 
let-7 maturation in undifferentiated cells. As differentiation progresses, Lin28 levels 
decrease allowing de-repression of let-7323.  Additionally, both Lin28a and Lin28b are 
targets of let-7, generating a double-negative feedback loop that functions as a 
developmental switch102. Let-7 has been identified as a tumour suppressor, 
downregulated in various types of cancer318,467–470.  Several important oncogenes 
including RAS, C-MYC and HMGA2 are targets of let-7268,317–319,471. In accordance, 
Lin28a and Lin28b have both been identified as oncogenes, overexpressed in ~15% 
of primary tumours and cancer cell lines472. Expression of both Lin28a/b is activated 
by binding of oncogene c-Myc and leads to repression of let-7132,472,473. 
Lin28b and Lin28a employ different mechanisms of regulation of let-7 (Figure 7). 
Lin28a is mainly localized to the cytoplasm, where its main mechanism of inhibition 
involves it binding to the GGAG motif present in the pre-let-7 CTL327. This binding 
leads to the subsequent recruitment of a terminal uridylyl-transferase (TUT), either 
TUT4 or TUT7, which catalyses the addition of a poly(U) tail to the 3’ of pre-let-
7327,474,475. This uridylation impedes Dicer cleavage as well as mark pre-let-7 for 
degradation by 3’-5’ exonuclease Dis-3l2327,329,330.   Additionally, reports suggest 
Lin28a binding can directly block let-7 processing  by Drosha100,101 and Dicer102,326. In 
contrast, Lin28b functions predominantly in the nucleus, where it binds to pri-let-7 
and blocks microprocessor cleavage in a TUT4/7 independent manner476.  
In vivo and in vitro studies have found that in addition to pre-let-7, Lin28 can bind to 
various pre-miRs with a conserved binding motif464,465,477,478. However, binding to a 
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conserved GGAG motif is not sufficient for Lin28a mediated uridylation, as this is 
dependent on the structure and sequence context surrounding the motif327,331. 
Importantly, it was previously shown in our group that in the case of miR-9, despite 
a lack of uridylation Lin28a was able to regulate its biogenesis in a uridylation-
independent manner383. 
Mir-9 is an evolutionarily conserved miRNA479.  Studies of miRNA expression profiles 
have identified it as a brain-enriched miRNA16,459,480. MiR-9 has important roles in 
neural differentiation481–485. Like let-7, miR-9 targets TLX inhibiting self-renewal of 
neural progenitors and promoting differentiation. In turn, TLX represses miR-9 
expression, forming a double negative feedback loop483. Expression of miR-9 and 
brain-enriched miR-124 in cultured neural progenitors drive neurogenesis whilst 
preventing gliogenesis481. Additionally, generation of miR-9 deficient mice showed 
that it orchestrates neurogenesis in the telencephalon by targeting multiple genes 
involved in neural progenitor proliferation and differentiation482. Furthermore, the 
importance of miR-9 and miR-124 in neural fate determination is illustrated by their 
ability to transform adult fibroblasts into neurons484. 
MiR-9 is under transcriptional regulation of REST and CREB transcription factors. REST 
inhibits the expression of miR-9 in undifferentiated cells, whilst dismissal of REST and 
activation of CREB trigger transcription of miR-9 during differentiation485. Previous 
studies in our group found an expected increase in both pri-miR-9 and mature miR-9 
levels during neural differentiation of P19 cells. However, the increase in pri-miR-9 
levels was much higher than that of mature miR-9, suggesting that transcriptional 
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regulation of miR-9 was accompanied by post-transcriptional regulation383. Using RP-
SMS, Lin28a was identified as binding the miR-9 CTL in undifferentiated cells. 
Additionally, siRNA mediated depletion of Lin28a led to an increase in miR-9 levels. 
Importantly, constitutive expression of Lin28a in P19 cells subject to retinoic acid (RA) 
induced neural differentiation led to a significant reduction in levels of let-7 and miR-
9 in late stages of differentiation. However, when GFP-tagged Lin28a was 
constitutively expressed in the same setting, let-7 levels showed a 4-fold reduction, 
but miR-9 levels remained unchanged. This indicates these miRNAs are regulated 
through different mechanisms. Indeed, further in vitro processing and uridylation 
assays showed Lin28a destabilizes miR-9 in a uridylation-independent manner383. 
To better understand these distinct mechanisms of regulation, in this study binding 
of Lin28a to let-7 and miR-9 was explored in further detail. The inability of GFP-tagged 
Lin28a to regulate miR-9 processing suggests that different domains of the protein 
could be involved in binding and it was important to elucidate if this was the case. 
Furthermore, Lin28a regulation of miR-9 processing by a novel mechanism poses the 
question of how extensive the role of Lin28a in miRNA biogenesis is. Therefore, the 
effects of constitutive expression of Lin28a in global miRNA levels were explored.  
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Differential binding of Lin28 truncated mutant to pre-let-7a-1 and pre-miRNA-9 
Structure probing experiments with lead ions and T1 and V1 ribonucleases, carried 
out in our group, identified different Lin28a binding motifs in pre-let-7a-1 and pre-
miR-9 (Figure 25). Lin28a footprinting showed binding to pre-let-7a-1 around well-
known AGGG and GGAG motifs, which are known to interact with Lin28 CSD and zinc 
fingers respectively326,486–488. Interestingly, despite possessing a GGAG motif, Lin28a 
footprinting indicated that the interaction with pre-miR-9 mostly occurred at the GU-
rich region in the CTL. 
In an effort to better understand whether the same Lin28a domains were responsible 
for both of these interactions, truncated T7-tagged Lin28a constructs with different 
Figure 25 Structure and Lin28a binding motifs of pre-let-7a-1 and pre-miR-9. Schematic 
representation of pre-let-7a-1 and pre-miR-9. Lin28a binding motifs identified by footprinting 
analyisis are marked in bold orange letters. 
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configurations of the CSD and zinc fingers were generated for use in RNA pulldown 
assays (Figure 26). Truncated Lin28a proteins were expressed in HeLa cells.  
 
RNA pulldown assays were carried out by incubating beads coupled with either 
pre-let-7a-1 or pre-miR-9 with total protein extracts from HeLa cells overexpressing 
each of the Lin28a truncation (Figure 27). Both pre-let-7a-1 and pre-miR-9 were able 
to pull down full length Lin28a as well as Lin28a with truncated C and N termini but 
containing both the CSD and the zinc fingers (24-190). This was expected as both pre-
Figure 26 Expression  of Lin28a truncations. Western blot showing the expression of T7-tagged 
Lin28a in HeLa cells. Lane labelled WT represents T7-tagged full length Lin28a. Lanes labelled 
1-6 represent Lin28a truncations. These numbers correspond to those in the left of the bottom 
panel. The bottom panel illustrates the domains contained by individual Lin28a truncations as 
well as the amino acids encompassed, as indicated to the right of the panel. CSD= cold-shock 
domain, ZnF= zinc finger domain. 
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miRs have previously been shown to bind Lin28a. Pre-miR-9 however, was able to 
pull down Lin28a truncations encompassing the CSD much more efficiently than pre-
let-7a-1 (Figure 27). In particular, pre-miR-9 was able to pull down the truncation 
composed of amino acids 24-123 with a higher efficiency than the full-length protein, 
72% of input vs 52% of input. In contrast, pre-let-7a-1 entirely failed to pull down the 
same fragment. Additionally, pre-let-7a-1 pulled down Lin28a zinc fingers (123-209) 
twice as efficiently as pre-miR-9. This is consistent with the Lin28a footprint observed 
in structure probing experiments as the zinc finger domain has been implicated in 
binding to the GGAG motif486–488. Lin28a truncations containing partial CSD (1-74) and 
a single zinc finger (156-209) also showed slightly stronger binding to pre-miR-9. 
Taken together these results support the idea that pre-let-7a-1 and pre-miR-9 
interact with different Lin28a domains, with the zinc finger domain playing an 
essential role in pre-let-7a-1 binding whilst both the CSD and zinc finger domain show 
involvement in pre-miR-9 binding.  
Additional experiments in our group confirmed the GGAG motif was not important in 
Lin28a binding to pre-miR-9. Replacing the GGAG motif with UUUU resulted in a 
reduction of Lin28a binding to pre-let-7a-1, however this had no effect in Lin28a 
binding to pre-miR-9. Again, this is consistent with the previous results showing a 
larger importance of the zinc finger domain in binding to pre-let-7a-1, as this domain 





Figure 27 Differential binding of pre-let-7a-1 and pre-miR-9 to Lin28a truncations.  RNA 
pulldown assays carried out with beads coupled to pre-let-7a-1 (A) or pre-miR-9 (B). These 
beads were incubated with HeLa extracts overexpressing the respective Lin28a truncation, as 
indicated in the upper section of the panels with the numbers referring to the amino-acids 
present in that truncation (lanes 5-18). Above the lanes (I) indicates input (odd lanes) and (P) 
indicates pulldown (even lanes). Lanes 1-2 correspond to a beads-only control (no RNA), whilst 
lanes 3-4 marked as mock contained beads but no protein extract. (C) Quantification of Lin28a 
binding in RNA pulldown assays. Values are presented as percentage of input signal detected 
in the pulldown fraction and represent three independent experiments. The corresponding 
truncations and the domains they encompass are referenced in the schematic on the left of 
the panel.  
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Changes in expression of other miRNAs upon constitutive expression of Lin28 
Regulation of miR-9 by Lin28a during neuronal differentiation shows that its effects 
on neurogenesis are not limited to inhibiting processing of let-7 miRNAs. Lin28a has 
been shown to bind other pre-miRs296,464,465,477,478, but the full extent of its regulatory 
role in miRNA biogenesis during neural differentiation is not known. To determine 
which other miRNAs are under control of Lin28a, small RNA sequencing was 
performed on undifferentiated (day 0) and differentiated (day 9) P19 cells. Control 
P19 cells were compared to cells constitutively expressing both GFP-tagged Lin28a 
and untagged Lin28a.  The levels of mature miRNAs in differentiated and 
undifferentiated cells was determined and presented as a Day9/Day0 ratio. These 
ratios were then compared between FRT-P19 and GFP-P19 control cell lines and 
untagged and GFP-tagged Lin28a expressing cell lines (Figure 28). 
 The levels of many miRNAs were affected upon expression of untagged Lin28a; 
however, this was not the case for GFP-tagged Lin28a whose overexpression had a 
more modest effect which was restricted to a smaller number of miRNAs. This 
exclusive regulation by untagged but not GFP-tagged Lin28a is equivalent to what is 
observed for pre-miR-9. Importantly, small RNA seq data showed the expected 
reduction of let-7 levels upon constitutive expression of both untagged and GFP-
tagged Lin28a relative to control cell lines, meanwhile reduction in miR-9 levels 
occurred upon induction of untagged but not GFP-tagged Lin28a. This is consistent 
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with all experiments up to this point and validates the data obtained from small RNA 
seq.  
Figure 28 Lin28a regulates numerous miRNAs during neuronal differentiation. miRNA levels in 
undifferentiated cells (Day 0) and differentiated cells (Day 9) were obtained by small RNA 
sequencing. Scatterplots represent the ratio (log2) of individual miRNA levels in Day 9 vs Day 0 
for cells that constitutively express untagged Lin28a (A) or GFP-tagged Lin28a (B) compared to 
the same ratios in respective control cell lines. Data points in orange represent miRNAs which 
showed a difference in Day9/Day0 ratios between control and untagged-Lin28a greater than 




Positive regulation of miRNA levels by Lin28a  
Surprisingly, small RNA seq data revealed that many miRNAs are positively regulated 
by Lin28a. Constitutive expression of untagged Lin28a resulted in higher levels of 
various miRNAs in differentiated cells compared to control P19 cell lines. Expression 
of GFP-tagged Lin28a left the levels of the same  miRNAs unchanged. In order to 
validate these results, two upregulated miRNAs, miR-182 and miR-541 were selected. 
Small RNA-seq data showed that in control P19 cells, levels of these miRNAs decrease 
upon neural differentiation, however upon constitutive expression of untagged 
Lin28a this decrease was no longer seen with miR-541 and miR-182 levels maintained 
throughout differentiation(Figure 29). Expression of GFP-tagged Lin28a did not have 
the same effect. These results were validated by qRT-PCR (Figure 29). Importantly, 
RNA pulldown assays showed that both miRNAs could pull down Lin28a when 
incubated with Day 0 extracts (Figure 30). In contrast, pre-miR-16 could not pull down 







Figure 29 Upregulation of miR-541 and miR-182 by Lin28a. qRT-PCR validation of small RNA seq 
data showing upregulation of miR-541 and miR-128 by untagged Lin28a but not GFP-tagged 
Lin28a. Values represent three independent experiments. Student’s T-test was performed to 



























































Regulation of 14q32 miRNAs by Lin28a during neural differentiation 
One of the Lin28a upregulated miRNAs selected, miR-541, is part of cluster 14q32, 
previously shown to be subject to post-transcriptional regulation in this study. Whilst 
previous studies established a role for the 14q32 cluster during ischemia, this cluster 
also has important functions in neural differentiation with miRNAs in this cluster 
being enriched in the brain243,489,490. MiRNAs in this cluster vary in their temporal 
expression patterns in the brain; for instance, whilst miR-369 and miR-496 and miR-
543 are abundant in both neural progenitors and neurons, miR-134 is poorly 
expressed in neural progenitors and is upregulated upon differentiation243,247,248. 
Within the cluster, miR-134 has the best studied roles in neurogenesis, playing an 
essential role in the regulation of dendritic outgrowth243,247,491. However other 
Figure 30 RNA pulldown showing Lin28a binding to miR-541 and miR-182. Western blot 
showing RNA pulldown assays carried out with beads coupled to pre-miR-541 or pre-miR-182 
as indicated above the lanes. Additionally, beads coupled to pre-let-7a-1 were used as a 
positive control and pre-miR-16 coupled beads function as a negative control. Beads were 
incubated with undifferentiated (Day 0) P19 cell extracts. Lane 1 shows the input and lane 2 
contains the uncoupled beads control. DHX9 blotting served as a positive binding control.  
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miRNAs in the cluster have also been shown to be important in driving neural 
differentiation, including miR-369, miR-496, miR-543 and miR-376a245,489. MiR-541, 
shown here to be positively regulated by Lin28a, was shown to inhibit differentiation 
and neurite outgrowth through the targeting of Synapsin-I in a model of rat PC12 
cells492. However, the mechanism of this regulation remains unknown. 
Because of the roles of miRNA cluster 14q32 in neural development, as well as 
evidence of its post-transcriptional regulation and of upregulation of miR-541 by 
Lin28a, it was of interest to see if constitutive overexpression of Lin28a impacted 
other members of the cluster. For this, small RNA seq data for members of the cluster 
was analysed to obtain the ratio of these miRNAs in undifferentiated (Day 0) and 
differentiated cells (Day 9). These ratios were then compared between control cells 
and cells expressing constitutive untagged Lin28a (Figure 31). 
Most miRNAs in the 14q32 cluster showed downregulation upon differentiation in 
control FRT P19 cells, with levels showing a greater than two-fold reduction from Day 
0 to Day 9. However, some individual members showed little change or even a slight 
increase in their levels at Day 9 of differentiation with miR-496a being the only miRNA 
that exhibited a greater than two-fold increase upon differentiation. This is consistent 
with previous reports that show differences in the temporal expression of these 
miRNAs during neural development248. Interestingly, constitutive overexpression of 
Lin28a had a varied impact on 14q32 miRNAs. Three of the miRNAs were considered 
to be downregulated by Lin28a, meaning that the change in miRNA levels from day 0 
to day 9 is at least twice as high in control cells compared to Lin28a expressing cells. 
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Half of the miRNAs in the cluster did not show any changes between cell lines, 
suggesting they are not subject to any regulation by Lin28a. Twenty-two miRNAs in 
the 14q32 cluster showed upregulation by Lin28a. The majority of these miRNAs 
showed a strong reduction in their levels upon differentiation in control FRT cells, 
however in Lin28a expressing cells their levels remain constant throughout 
differentiation.  
However, miR-770 and miR-1180 showed constant levels in control cell lines but 
strong upregulation in Lin28a cells. Furthermore, miR-493 levels decreased by 75% in 
FRT cells, whilst in Lin28a cells they increased greater than two-fold.  
Taken together, this indicates that Lin28a expression has a mostly positive effect in 
the levels of 14q32 miRNAs. Whilst further studies are needed to determine whether 
the effect observed is a product of direct or indirect regulation by Lin28a, it is known 
that this cluster is transcribed as a single polycistronic cluster and therefore the 










Figure 31 Lin28a regulation of 14q32 miRNA cluster. Ratio of miRNA levels at Day 9 vs Day 0 
of differentiation determined by small RNA seq. The first column represents the fold change 
in control FRT P19 cells whilst the second column shows the fold change in P19 cells 
constitutively expressing Lin28a. Red cells indicate an increase in miRNA levels from Day 0 to 
Day 9 whilst blue cells indicate a decrease in levels. Numbers in bold represent a change of at 
least 2-fold. The third column shows the fold difference in the Day 9/Day 0 ratios of miRNA 
levels in control and Lin28a expressing cell lines. Yellow cells indicate a difference greater than 




Lin28a is well-known to regulate let-7 miRNAs during neurogenesis, in a uridylation 
dependent mechanism101,472,478. Whilst this mechanism is essential in the 
maintenance of ES cells, the roles of Lin28a in development are not limited to its 
regulation of let-7. Lin28a has been shown to directly bind mRNAs in ES cells 
enhancing the translation of genes involved in proliferation, survival and 
splicing464,493,494.  
Previously our group showed Lin28a to regulate brain-enriched miR-9 in a uridylation-
independent manner383. Mir-9 also has important functions in regulating neural 
differentiation481,483,484. Interestingly, constitutively expressed GFP-tagged Lin28a 
could repress let-7 biogenesis but had no effect on miR-9 levels, suggesting 
involvement of different Lin28a domains in binding and regulating both miRNAs383.  
Here, Lin28a truncations with different domain configurations were generated to 
further study the involvement of the CSD and the zinc finger domain in binding these 
miRNA precursors. RNA pulldown assays with pre-let-7 and pre-miR-9 coupled to 
agarose beads showed differences in their binding to Lin28a domains. Pre-miR-9 
bound to the Lin28a’s CSD with much higher affinity than pre-let-7, whereas pre-let-7 
pulled down the zinc finger domain twice as effectively as pre-miR-9 (Figure 27). 
These results were supported by further experiments showing the GGAG motif in the 
miR-9 CTL was not involved in Lin28a binding since the GGAG motif in the let-7 CTL 
has associates with the Lin28a zinc finger domain486–488. While GGAG is a preferred 
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Lin28a binding motif, previous work in our group has shown that a pre-let-7 mutant 
with a minimal CTL containing the GGAG motif could not bind Lin28a demonstrating 
that the structural context is important for this interaction331. This could explain why 
even though the GGAG motif is present in the miR-9 CTL, it is not involved in Lin28a 
binding.  
Binding of Lin28a to the CTL of let-7 leads to the recruitment of TUT4/7 resulting in 
uridylation of its 3’ end (Figure 7). This uridylation ultimately marks pre-let-7 for 
degradation by Dis3l2 exonuclease329,330. Previously, it was shown by our group that 
Lin28a regulates pre-miR-9 in a uridylation independent manner383. However, further 
experiments have shown that Dis3l2 is also involved in the regulation of miR-9, with 
in vitro studies showing it was capable of degrading miR-9. Furthermore, Dis3l2 
knockdown resulted in an increase of miR-9 levels. This differs to let-7 where 
knockdown of Dis3l2 results in an increase in pre-let-7 but does not affect mature let-
7 levels as Lin28a interaction can also directly block Dicer processing478. Again, this 
reveals differences in the mechanisms of regulation of Lin28a, showing it has a more 
robust control on let-7 levels. Further studies are necessary to fully elucidate the 
relationship between pre-miR-9, Lin28a and Dis3l2. Lin28a and Dis3l2 do not appear 
to interact in an RNA-independent manner329. In the case of pre-let-7, Lin28a 
mediated uridylation leads to recognition by Dis3l2 as this exonuclease favours 
uridylated substrates495. However, since regulation of miR-9 biogenesis is uridylation-




Aside from further defining the details of miR-9 regulation by Lin28a, this study 
showed that constitutive expression of untagged Lin28a impacts the levels of many 
additional miRNAs during neural differentiation of P19 cells (Figure 28). Like miR-9 
however, the levels of many of these miRNAs were not altered upon expression of 
GFP-tagged Lin28a, showing that interaction through the CSD could be important in 
their regulation. Additionally, unlike let-7 and miR-9 which are repressed by Lin28a, 
many miRNAs showed an increase in their levels in differentiated cells upon 
constitutive expression of untagged Lin28a. This suggest that Lin28a is carrying out a 
positive regulatory role.  The levels of two Lin28a up-regulated miRNAs, miR-541 and 
miR-182 were validated through qRT-PCR (Figure 29). Additionally, RNA pulldown 
assays showed that these miRNAs interact with Lin28a. Whilst this suggests that at 
least some of the upregulated miRNAs could be directly regulated by Lin28a, the 
change in the levels of some miRNAs upon expression of Lin28a in differentiated cells 
could be a product of indirect regulation.  
Lin28a is a pluripotency factor, quickly lost after the onset of differentiation. P19 cells 
are pluripotent embryonic carcinoma cells that constitutively express Lin28a, 
therefore overexpression of Lin28a should not affect their genetic programming. 
However, upon differentiation with RA forced expression of Lin28a could affect their 
differentiating potential, resulting in a state that is not fully differentiated which 
contributes to the alteration of miRNA levels with respect to wildtype P19 cells. 
Whilst the RA-mediated differentiation method used in this study does result in the 
formation of embryonic bodies at day 4 and subsequently cells with neuron-like 
morphology at day 9 in both wildtype and Lin28a overexpressing cells, differences 
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were observed. Specifically, the size of embryonic bodies of Lin28a but not Lin28a-
GFP expressing cells were consistently found to be smaller383. 
Going forward it would be important to differentiate between direct regulation by 
Lin28a and changes brought about indirectly. Determining whether these miRNAs are 
able to interact with Lin28a through the use of RNA pulldown assays or RNA-
immunoprecipitation would be useful in making this differentiation. Additionally, it 
would be informative to determine whether the addition of Lin28a to in vitro 
processing reactions with upregulated and downregulated pri-miRNAs, is sufficient 
to produce a positive or negative effect respectively on their processing 
 Additionally, it is of great interest to elucidate the mechanisms behind positive 
regulation by Lin28a, including the structural and sequence requirements of 
regulated miRNAs, the effect of Lin28a binding on pre-miR stability and the 
interacting partners of Lin28a. These are all intriguing questions that provide future 
research avenues. 
Mir-541 is one of the miRNAs upregulated by Lin28a. It has been shown to be 
important in the differentiation of PC12 cells, through targeting of Synapsin-I492. PC12 
cells are derived from a rat adrenal tumour and easily differentiate into neuron-like 
cells upon treatment with nerve growth factor (NGF). Treatment with NGF resulted 
in a reduction of miR-541 which led to decreased Synapsin-I levels and increased 
differentiation. MiR-451 forms part of the 14q32 cluster of miRNAs, a brain-enriched 




In general, the cluster appeared to be downregulated upon differentiation (Figure 
31). Because the cluster is transcribed as a single polycistronic unit, this could be an 
effect of transcriptional rather than post-transcriptional regulation. However, 
constitutive expression of Lin28a had different effects on individual members of the 
cluster. Approximately half of the miRNAs in the cluster showed increased levels in 
Lin28a expressing cells and three miRNAs in the cluster were negatively regulated by 
Lin28a with the rest of the members showing no effect.  
Similarly, to what was previously observed after induction of HLI, this pattern of 
regulation was unrelated to the miRNAs position within the cluster (Figure 32). In the 
future it would be interesting to explore the sequence and structural motifs defining 
the effect of Lin28a on individual members of the cluster. The widespread effects of 
Lin28a expression on the levels of numerous miRNAs belonging to a cluster involved 
in neurogenesis pathways supports the idea that the roles of Lin28a in neural 
development are widespread and not yet fully understood. 
Lin28a affected miRNAs are likely to be subject to additional levels of regulation. 
Previous studies showed that replacing the terminal loop of let-7 with the miR-16 
terminal loop was sufficient to abolish Lin28a interaction and resulted in de-
Figure 32 Lin28a regulation of 14q32 miRNAs is independent of their position within the cluster. 
Schematic representation of 14q32 cluster colour coded by Lin28a regulation of individual 
miRNAs. Blue miRNAs are upregulated by Lin28a, red miRNAs are downregulated by Lin28a, 
and yellow miRNAs are unaffected. No data was available for miRNAs in grey. 
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repression of let-7. However, when the same experiments were conducted with miR-
9, substitution of the terminal loop eliminated Lin28a binding but did not de-repress 
miR-9 processing383. This suggests that other factors are controlling the repression of 
mature miR-9. In a similar way, despite showing that Lin28a upregulates miR-541, 
knockdown of Lin28a did not repress miR-541 meaning it is likely other factors could 
be ensuring its processing. Because miRNA levels need to be carefully controlled 
during development, cells are likely to employ  multiple regulatory mechanism to 
ensure correct temporal expression of miRNAs. Both upregulation and 
downregulation of miRNA levels can have significant developmental effects, for 
example both low and high levels of miR-134 during neurogenesis can compromise 
proper dendritic outgrowth243. Lin28a is unlikely to be the only factor controlling the 
regulation of the miRNAs affected by its constitutive expression. However, it is clear 
that Lin28a exerts important regulatory functions during neural differentiation and 
does so through various mechanisms. Elucidating the full details of these mechanisms 













Oleic acid regulation of miRNA biogenesis by inhibition of RNA binding 
activity of RBPs 
As our knowledge of RBPs involved in miRNA biogenesis expands, we have also begun 
to better understand how RBP:miRNA interactions are modulated in a physiological 
context, allowing miRNA expression patterns to adapt according to the cellular 
environment. The RNA-binding activities of RBP proteins are often modulated via 
their interactions with proteins in cellular signalling pathways; examples of this are 
seen in miRNA biogenesis regulation in the inhibition of p72 binding to pri-miRs by 
YAP in the Hippo signalling pathway or contrarily by SMAD signalling proteins 
increasing the binding of p68 to pri-miRs290,291.  But as the repertoire of known RBP 
grows, new mechanisms regulating their binding to RNA also emerge. This is seen 
with the increasingly growing group of metabolic enzymes that moonlight as RBPs; 
the RNA binding activity of these proteins is frequently regulated by the cellular 
metabolites that function as their substrates and co-factors352,354.  
Recently, Clingman et al. showed that Oleic Acid (OA) was able to inhibit the RNA 
binding of RNA-binding protein Musashi homolog 1 (MSI1)382. OA is a naturally 
occurring 18 carbon mono-unsaturated fatty acid with a cis double bond in the ω-9 
position (Figure 33). It is the most common monounsaturated fatty acid in plants and 
animals, with a normal physiological serum concentration in humans ranging in the 
high μM to low mM range496,497. OA was identified in a screen of over 30,000 
components as a specific inhibitor of MSI1, an RBP involved in neurogenesis. This 
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inhibition was mediated through binding of OA to the first of two RNA-recognition 
motifs (RRM)382.  
RRM domains are comprised of approximately 90 amino-acids and contain two 
consensus sequences termed RNP1 and RNP2 of eight and six conserved residues 
respectively. The RRM folds into a compact globular domain consisting of a β-sheet 
made up of four antiparallel β strands flanked on one side by two α-helixes. 
Conserved residues responsible for interaction with RNA are found on the β-sheet498. 
Clingman et al.382 propose that OA binds in a hydrophobic cavity found in the surface 
of the MSI1 RRM1 α-helixes, opposite the RNA-binding surface. This binding then 
allosterically induces a conformational change that results in the inhibition of RNA 
binding by MSI1382.  
The  inhibitory potential of OA was shared with other unsaturated fatty acids of 18-
22 carbons in length which shared the ω-9 cis double bond; however, elaidic acid 
(EA), the trans-isoform of OA with similar molecular properties was unable to inhibit 
MSI1 RNA binding382 . 
MSI2 is a homologous protein to MSI1; they share 75% amino acid identity and are 
expressed in partially overlapping patterns499. RNA-binding inhibition by ω-9 fatty 
acids was conserved for MSI2382. It was previously shown in our group that MSI2 
together with HuR, post-transcriptionally regulates the biogenesis of brain-enriched 
miR-7296. HuR is a ubiquitously expressed member of the Hu protein family, whose 
members possess three RRM motifs. HuR plays a role in stabilizing mRNA by binding 
to AU-rich elements (AREs)500. 
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MiR-7 is a known tumour suppressor, that targets oncogenic signalling proteins 
involved in diverse processes including cell cycle, proliferation and metastasis501. It 
directly regulates the epithelial growth factor receptor (EGFR) as well as upstream 
regulators of the Akt pathway, both of which are hyperactive in glioblastomas and 
are associated with aggressive phenotypes; in accordance miR-7 appears 
downregulated in glioblastoma297. MiR-7 has also been found to be downregulated 
in patients with Parkinson’s disease (PD) as well as in PD animal models180. A role for 
miR-7 in PD has been attributed to its regulation of the SNCA gene which encodes α-
SYN, a key protein in PD pathogenesis whose overexpression is deleterious to 
dopaminergic neurons180,502.  
MiR-7 resides in intron 15 of the hnRNP K mRNA and whilst this transcript is 
expressed ubiquitously, miR-7 is expressed predominantly in neural and pancreatic 
tissues16,503. Conversely, MSI2  is expressed across most tissues but is not found in 
the brain and is almost undetectable in the liver296. HuR mediates the recruitment of 
MSI2 to the CTL of pri-miR-7, where this complex increases the rigidity of the stem-
loop structure which in turn inhibits microprocessor cleavage296. Given the inhibitory 
effect of OA on MSI2 RNA-binding, it was of interest to explore if it could disrupt the 
Figure 33 Structure of Oleic and Elaidic acid. Representation of the Structure of Oleic acid (OA) 
and Elaidic acid (EA). EA is a trans-isomer of OA, both are mono-unsaturated 18-carbon fatty 
acids with an ω-9 double bond. 
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binding of the HuR/MSI2 complex to the CTL of pri-miR-7, thereby allowing its 
processing (Figure 34).  
Inhibition of pre-miR-7/protein complexes by Oleic and Elaidic acid 
As a first step in exploring the inhibition by OA of MSI2/HuR RNA-binding, an 
electrophoretic mobility shift assay (EMSA) was performed, incubating radiolabelled 
pre-miR-7 with HeLa whole cell extracts and increasing concentrations of OA.  The 
same assay was carried out with EA, the trans-isoform of OA, which previously had 
been reported to be unable to inhibit MSI2 RNA-binding.  Incubating pre-miR-7 with 
HeLa extracts in the absence of OA, resulted in a shift of the free RNA, indicating the 
formation of pre-miR-7,protein complexes. Upon addition of increasing 
concentrations of OA there was a corresponding decrease in the signal intensity of 
Figure 34 Regulation of pri-miR-7-1 processing by HuR and MSI2 and its inhibition by Oleic acid. 
HuR and MSI2 form a complex that binds to pri-miR-7-1 CTL (in red) inhibiting its processing by 
the microprocessor. If oleic acid binding directly to MSI2 can displace the HuR/MSI2 complex 
from the pri-miR-7-1 CTL, this would in turn allow microprocessor processing.  
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the shifted complexes (Figure 35). This result suggests that OA is inhibiting the 
binding of proteins to pre-miR-7. 
Contrary to what had been previously observed, increasing concentrations of EA had 
a similar effect on the signal intensity of the shifted free RNA, indicating a similar 
inhibition to that of OA. When densitometry analysis was performed on the EMSA 
results, the inhibitory effect of EA on complex formation was shown to be relatively 
weaker to that of OA at similar concentrations with a significantly lower signal in OA 
treated cells at concentrations of 500μM (Figure 36). 
 
  
Figure 35 Inhibition of pre-miR-7/protein complexes by oleic and elaidic acid. EMSA was carried 
out with radiolabelled pre-miR-7 incubated with HeLa cell extracts and increasing 
concentrations of oleic acid (lanes 1-5) or elaidic acid (6-10). Lanes 1 and 6 represent controls 
incubated without cell extracts. Lanes 2 and 7 represent extracts incubated only with HeLa 
extracts but not OA/EA. The arrow highlights the shifted pre-miR-7/protein complexes. 
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Oleic and Elaidic acid inhibition of additional pri-miR/protein complexes 
Additional EMSA experiments were carried out incubating HeLa extracts with three 
different radiolabelled pre-miRs, pre-let-7, pre-miR-16 and pre-miR-495, to 
determine whether the inhibitory effects of OA and EA treatment was specific to 
protein/RNA complexes with pre-miR-7. Incubation of all three pre-miRs with HeLa 
extracts produced a strong shifted signal, indicating the formation of pre-miR/protein 
complexes (Figure 37). Importantly, no reduction in the formation of pre-let-
7/protein complexes was observed upon treatment with either OA or EA, whilst the 
signal for the shifted pre-miR-16/protein complexes was reduced at the high 
Figure 36. Quantification of pre-miR-7/protein complexes. Densitometry analysis of EMSA. 
Controls represent the signal intensity of shifted pre-miR-7/protein complexes in the absence 
of fatty acids. Quantification of the signal of shifted pre-miR-7/protein complexes after 
treatment with oleic and elaidic acid is presented as a percentage relative to controls.  These 
results represent three separate experiments. Students t-test was used to calculate 
significance with *=p<0.05  
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concentrations of both OA and EA (Figure 37-38). This indicates some level of in vitro 
specificity, for the inhibitory actions of OA and EA.  
In the assays carried out with pre-miR-495, a miRNA belonging to polycistronic miRNA 
cluster 14q32, a concentration dependent reduction in shifted complexes was 
observed upon treatment with OA (Figure 37 C). Although a slight reduction was also 
observed in samples incubated with EA, this was much smaller and remained 
constant for all concentrations of EA. This could suggest that these fatty acids are 






Figure 37 Inhibition of additional pre-miR/protein complexes by oleic and elaidic acid. EMSA with 
radiolabelled pre-let-7 (A), pre-miR-16 (B) and pre-miR-495 (C) incubated with HeLa extracts 
and increasing concentrations of OA (1-5) or EA (2-10). Lanes 1 and 6 are control EMSA with 
no protein extract. Lanes 2 and 6 are incubated with HeLa extract but no fatty acid. Images 




Figure 38 Quantification of pre-miR/protein complexes. Densitometry analysis of EMSA with 
radiolabelled pre-let-7 (A), pre-miR-16 (B) and pre-miR-495 (C). Controls represent the signal 
intensity of shifted pre-miR/protein complexes in the absence of fatty acids. Quantification of 
the signal of shifted pre-miR/protein complexes after treatment with oleic and elaidic acid is 
presented as a percentage relative to controls.  These results represent three separate 
experiments. Students t-test was used to calculate statistical significance with *=p<0.05   
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Validation of specific RNA-binding proteins in pre-miR-7/protein complexes 
Following the EMSA results, identification of HuR and MSI2 in the shifted pre-miR-
7/protein complexes was sought. To do this, a modified EMSA assay termed western 
blot-combined EMSA (WEMSA) was performed. In this approach, EMSA assay were 
carried out incubating non-radiolabelled pre-miR-7 with HeLa whole cell extracts and 
increasing concentrations of OA or EA. Following separation of RNA complexes, the 
gel was then transferred onto a nitrocellulose membrane and probed with antibodies 
specific to selected proteins. The WEMSA showed a strong signal for HuR in the 
shifted band, positively identifying it as a component of the pre-miR-7 complexes. 
HuR signal decreased upon treatment with OA in a concentration dependent manner. 
Comparatively, treatment with EA showed a much smaller reduction in signal 
intensity of HuR in the protein/pri-miR-7 complexes (Figure 39 A). This discrepancy 
confirmed some degree of specificity in the RNA-binding inhibitory activity of fatty 
acids in vitro. Unfortunately, blotting against MSI2 produced a signal that was too low 
for detection and analysis. 
Additionally, WEMSA was used to probe for DExD/H-box helicase DHX9. DHX9 is an 
NTP-dependent helicase with functions in multiple aspects of RNA biology, including 
miRNA biogenesis. Aside from its core helicase domain, DHX9 contains two double-
stranded RNA binding domains (dsRBD) at its N-terminal504. OA and EA also resulted 
in a decrease in DHX9 present in the complexes, but did so to a smaller extent (Figure 




Figure 39 Validation of RNA-binding proteins in pre-miR-7/protein complex. Western-blot 
combined EMSA (WEMSA) was performed on the EMSA in Figure 35. The EMSA gel was 
transferred unto a nitrocellulose membrane and blotted with antibodies against HuR (A) 
and DHX9 (B). Lanes 1 and 6 represent controls where no protein extracts were present. 
Lanes 2 and 7 represent pre-miR-7 incubated with protein extract but no fatty acids. 
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RNA pulldown experiments corroborated the effects of OA and EA on the binding of 
RRM-containing proteins to the CTL of miR-7. HeLa whole cell extracts were 
incubated with miR-7 CTL coupled to agarose beads and increasing concentrations of 
OA and EA. This incubation was followed by stringent washes, permitting the 
identification of specific interactions. The binding of several RRM-containing proteins 
previously identified to bind specifically to the miR-7 CTL (namely HuR, MSI2 and 
hnRNP A1)296 was then analysed by western blot (Figure 40). Incubation with 500µM 
concentrations of OA, but not lower concentrations, completely abolished the 
binding of all three proteins. EA similarly abolished binding of HuR and hnRNPA1 
whilst reducing MSI2 binding at equivalent concentrations. Inhibition of DHX9 
binding to miR-7 CTL was also probed and was unaffected by both OA and EA 
treatment. This suggests that the inhibitory effect of these fatty acids on RNA-binding 





Figure 40 Inhibition by oleic and elaidic acid of RBPs binding miR-7-1 CTL. Western Blot analysis 
of RNA pulldown assays using miR-7-1-CTL coupled beads incubated with HeLa cell extracts and 
OA/EA treatment. Binding of RBPs MSI2, HuR, hnRNPA1 and DHX9, was analysed using specific 
antibodies as indicated on the left-hand side of the panel. Lanes 1-9 correspond to OA treatment 
and lanes 10-18 correspond to EA treatment. Lanes 1 and 10 represent loading control of HeLa 
extracts. In lanes marked B (Beads only), beads were not coupled to RNA,  whereas in lanes 
marked P (pulldown) beads where coupled to miR-7-CTL. Concentrations of OA and EA used for 
each lane are indicated above the image were control indicates no fatty acid treatment. 
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Effects of oleic and elaidic acid on in vitro pri-miR-processing 
Binding of an HuR/MSI2 complex regulates the biogenesis of miR-7 by binding to its 
CTL, stabilizing the stem-loop structure and inhibiting microprocessor processing296. 
Given this, it was analysed whether the displacement of this complex from the miR-7 
CTL by OA rescued pri-miR-7 processing. This was done using in vitro processing 
assays, where radiolabelled pri-miR-7 was incubated with HeLa extracts and 
increasing concentrations of OA or EA. As expected, no processing of pri-miR-7 was 
observed in the absence of OA or EA, illustrated by the absence of pre-miR-7 in the 
samples. Upon incubation with 1mM concentrations of both OA and EA, a pre-miR-7 
product could be detected, indicating rescued processing of pri-miR-7 (Figure 41 A-
B). This displays specificity in the displacement of RBP by fatty acid treatment as the 
microprocessor was still able to bind and process pri-miR-7.  
Equivalent assays were carried out with pri-miR-16; a miRNA with tumour suppressor 
roles that is ubiquitously expressed at high levels16,230 and which remained 
unchanged after MSI2 and HuR knockdown in previous studies296. Intriguingly, 
treatment with OA or EA produced a concentration-dependent inhibitory effect on 
pri-miR-16 in vitro processing, contrary to the positive effect observed on pri-miR-7 
processing (Figure 41 C-D). This effect could potentially be explained by OA and EA 
displacing RRM-containing RBPs that promote miR-16 processing. Indeed an example 
of an RRM containing RBP, RNA-binding protein 3 (RBM3), has been shown to bind 
pre-miR-16313. Additionally, overexpression and knockdown experiments show a 
positive correlation between levels of RBM3 and mature miR-16313. It is likely that 
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like RBM3, other yet unknown RRM-containing proteins can bind miR-16 precursors 
regulating their processing. In this way, the regulatory effects of long-chain fatty acids 
could extend far beyond the regulation of miR-7 biogenesis.  
Figure 41 Induction of pri-miR-7 processing and inhibition of pri-miR-16 processing by oleic and 
elaidic acid. In vitro processing assays for pri-miR-7 (A-B) and pri-miR-16 (C-D). Lane 1 in all 
panels corresponds to MW ladder. Lane 2 in all panels corresponds to pri-miR-7/16  without 
HeLa extracts and lane 3 corresponds to pri-miR-7/16 and HeLa extract with no OA or EA 
treatment. In lanes 4-6 pri-miR-7/16 was incubated with HeLa extracts and increasing 
concentrations of OA (A,C) or EA (B,D). 
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Rescue of mature miR-7 production in cellular cultures by OA treatment 
After establishing OA has the potential to inhibit the binding of MSI2 and HuR to 
miR-7 CTL as well as rescuing its processing in vitro,  experiments were conducted to 
determine whether the same was true in a cellular culture. Previously it was shown 
that production of mature miR-7 is blocked in HeLa cells, and that this production 
was rescued by the knockdown of HuR or MSI2296. To determine whether 
displacement of these proteins by OA treatment could produce an analogous effect, 
levels of mature miR-7 were measured by qRT-PCR in HeLa extracts incubated with 
increasing concentrations of OA. Cells were grown for 24 hours before media was 
substituted for Opti-mem and OA was added in increasing concentrations. Because 
OA was resuspended in DMSO equivalent concentrations of DMSO were added to 
control cells.  
A modest but significant increase in levels of mature miR-7 was observed at 
incubation with concentrations of 500µM and 1mM OA (Figure 42). Additionally, 
levels of two other miRNAs were monitored; let-7 for which EMSA analysis showed 
no reduction in protein/pre-let-7 complexes following OA treatment and miR-423 
which is a stably expressed miRNA used as a control in qRT-PCR420–423. No change in 
the levels of either mature miR-423 or mature let-7 were detected reinforcing the 
observed specificity of the effect of OA treatment in miRNA biogenesis in cellular 






Figure 42 Increase in in vivo levels of miR-7 upon oleic acid treatment. Total RNA was extracted 
from cells treated with increasing levels of OA. Levels of mature miRNAs in these samples were 
measured by qRT-PCR. The values presented correspond to the change in levels of miRNAs 
compared to control cells treated with DMSO. All  values were normalized to miR-16. Students 




OA was previously reported to inhibit binding of MSI1/MSI2 to RNA382; MSI2 in 
complex with HuR blocks processing of miR-7 contributing to its tissue-specificity296. 
Here, it was shown that OA can block the formation of miR-7 CTL/protein complexes 
observed in EMSA. Furthermore, HuR was positively identified in as a member of 
these shifted complexes showing that OA inhibits HuR binding to the CTL of miR-7. 
This was further confirmed by RNA pulldown experiments which additionally  showed 
inhibition of MSI2 binding to miR-7 CTL. Along with inhibiting MSI2/HuR binding, OA 
treatment increased in vitro processing of pri-miR-7 and production of mature miR-7 
in cellular cultures in a concentration dependent manner, suggesting that 
displacement of the MSI2/HuR complex can influence biogenesis of miR-7.  
Unlike in the previous study by Clingman et al.382 which showed no inhibition of 
MSI1/MSI2 binding by EA, a concentration-dependent reduction of the pre-miR-
7/protein complexes upon EA treatment was also observed, although densitometry 
analysis revealed it was comparatively smaller, specifically at the 500μM 
concentrations. Similarly, in RNA pulldown experiments, high concentrations of EA 
completely displaced HuR and reduced MSI2 binding respectively.   
This discrepancy could potentially be attributed to the higher concentrations of OA 
and EA used in our study. In the previous study other fatty acids of 18-22 carbons in 
length were also able to inhibit MSI1-RNA binding with varying strength, whilst 
saturated fatty acids or those with longer carbon chains were unable to inhibit RNA 
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binding382. This variation on inhibitory potential was proposed to depend on the 
ability of the given fatty acid to enter the hydrophobic cavity opposite the RNA-
binding surface and establish extensive contact with the protein; the trans-bond in 
EA was suggested to diminish surface contact with MSI1. However, it is possible that 
this reduced contact is enough to produce inhibition of RNA-binding, although 
weaker, therefore requiring higher concentrations of EA.  
Additionally, differences in RRM-containing proteins could make them more 
permissive to inhibition by trans-fatty acids. RRM-domains are conserved structurally 
but not in sequence, meaning the presence of differing side chains in the alpha-helical 
surface could impact their interaction with long-chain fatty acids. This is of particular 
relevance when considering the loss of pre-miR-7/protein complexes observed in 
EMSA upon treatment with EA since there are proteins other than MSI2 in these 
complexes, including HuR.   
RRM domains are highly abundant in eukaryotic organisms, being present in >50% of 
human RBPs505. Here, RNA pulldown assays showed that OA and EA inhibited the 
binding of two RRM-containing proteins, HuR and hnRNP A1, to pre-miR-7 in addition 
to MSI2. This suggests that the inhibitory potential of long-chain fatty acids such as 
OA and EA could extend far beyond MSI1/MSI2. Similarly, EMSAs carried out with 
pre-miR-16 showed inhibition of miRNA/protein complexes by OA and EA in a 
concentration dependent manner, whilst OA additionally inhibited the formation of 
pre-miR-495/protein complexes. These EMSAs are insufficient to establish the 
identity of the proteins in the shifted pre-miR/protein complexes but is reasonable 
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to assume they are not restricted to MSI2 and HuR. This is further supported by in 
vitro processing assays for pri-miR-16 which show that contrary to that observed for 
pri-miR-7, incubation with OA and EA actually inhibit its processing. This suggests that 
the protein bound to pre-miR-16 being displaced by OA/EA are promoting rather than 
inhibitory factors. Additionally, miR-495 is a member of the 14q32 cluster, for which 
protein factors binding differentially upon starvation were previously sought in this 
study using RNA pulldown followed by SILAC mass spectrometry. Interestingly, one 
of the proteins validated to bind pre-miR-495 was CIRBP, a protein which possess an 
RRM domain in its N-terminus. Additionally, other RRM-containing proteins were 
identified to bind pre-miR-495 by mass spectrometry, including RBM3 and RBM27.  
In the future, it would be of interest to explore the presence of these protein in the 
pre-miR-495/protein complexes inhibited by OA. 
These experiments revealed, the inhibitory potential of OA and EA against selected 
RRM-containing proteins. Whilst OA and EA also reduced binding of DHX9, a protein 
which does not contain an RRM domain, they had a weaker effect on this interaction. 
Importantly, in vitro processing assays showed the microprocessor remained 
functional in the presence of OA/EA, indicating it was still able to bind to pri-miR-7 
and process it into pre-miR-7. Additionally, EMSA with pre-let-7 showed no inhibition 
of pre-let-7 protein complexes by OA/EA, showing that this inhibition is dependent 
on the RNA substrate. Finally, although both OA and EA were found to inhibit RNA 
binding of RRM containing proteins, they did exhibit some differences in doing so. 
Namely, only OA was able to inhibit pre-miR-495/protein complexes as well as 
producing a stronger inhibition of pre-miR-7/protein complexes than EA. In RNA 
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pulldown assays whilst EA showed a reduction in MSI2 binding to pre-miR-7, only OA 
completely abolished this binding. Altogether, this shows that the presence of long-
chain fatty acids does not trigger a global inhibition of RNA-binding, but rather results 
in specific inhibition of RNA-binding dependent on the identity of the fatty-acid, the 
RNA-binding protein and the RNA substrate in question. 
The results shown here confirm the initial reports of OA as a regulator of RNA-binding 
activity of MSI2 whilst presenting the possibility that this regulation could extend 
beyond what was first thought, influencing the RNA-binding activities of a larger set 
of RRM-containing proteins. Additionally, they show that OA can influence the 
biogenesis of at least miR-7, and potentially other miRNAs.  This opens up the 
possibility of miRNAs as intermediaries between metabolism and gene expression, 
adding another component to this growingly interconnected regulatory network. 
In glial cells, OA caused a decrease in lipogenesis and cholesterologenesis which 
coincided with a reduction in the expression of acetyl-coenzyme A carboxylase (ACC) 
and 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), key enzymes in 
lipogenesis and cholesterologenesis respectively506. Similarly, a decrease in 
expression of lipogenic enzymes is observed in rats and mice fed with a diet rich in 
OA507,508. Whilst these changes are likely to partially mediated through direct 
activation by OA of the nuclear receptor transcription factor peroxisome proliferator-
activated receptor alpha (PPARα)508, this doesn’t explain the full extent of changes 
seen in the levels of lipogenic and cholesterologenic enzymes and it is tempting to 
speculate that these are in part mediated indirectly, through changes in RNA 
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processing (including miRNA biogenesis). OA is further linked to a variety of 
pathological conditions. Colorectal cancer patients showed significantly higher 
proportions of OA compared to controls509, whilst OA drove proliferation and 
chemoresistance in prostate cancer510. Reduced levels of OA were found in brains of 
patients with Alzheimer’s disease511,512. Additionally, α-SYN, a protein genetically and 
pathologically linked with Parkinson’s disease can cause an increase in OA 
production513. This protein has been identified as a miR-7 target502, presenting the 
possibility of a positive feedback loop where an α-SYN mediated increase in OA leads 
to a decrease in miR-7 levels resulting in even higher levels of α-SYN. 
 It is hard to speculate what proportion of the effects of OA on cellular metabolism 
can be attributed to its impact on miRNA biogenesis, both under normal and 
pathological conditions. However, it would be of great interest in the future to further 
explore the impact of OA on global miRNA levels and further downstream changes in 
gene expression, to begin to answer these questions. It is likely that changes in miRNA 
profiles is one of many ways that OA regulates cellular metabolism, but when dealing 
with complex multifactorial diseases this could prove important clues as well as 





This study has explored different aspects of the post-transcriptional regulation of 
miRNA biogenesis in specific contexts. By exploring the regulation of cluster 14q32 in 
response to ischemia and cellular starvation, HADHB and CIRBP were identified as 
novel factors involved in the regulation of miRNA biogenesis. These proteins showed 
specific regulation of the pre-miR to mature miRNA step of the miRNA biogenesis 
pathway.  
As well as identifying novel proteins, this study further explored the roles of Lin28a 
in regulating miRNA biogenesis during neurogenesis of P19 cells. Lin28a has well 
described roles in the inhibition of let-7 biogenesis,  however here it was shown that 
it regulates a second miRNA involved in neurogenesis, miR-9, and does so using a 
different mechanism. Extending this further, it was shown that Lin28a influences the 
levels of various miRNAs during neuronal differentiation, doing so in positive and 
negative manners. 
Finally, this study also looked at the inhibitory effect of oleic and elaidic acid on the 
interaction of pre-miR terminal loops and regulatory protein complexes. Specifically, 
it was shown that oleic and elaidic acid are able to displace inhibitory factors from 
the miR-7 CTL, resulting in increased in vitro processing of pri-miR-7 and an increase 
of miR-7 levels in cultured cells. Additionally, oleic and elaidic acid were able were 
able to displace protein complexes from other pre-miR CTLs and, contrary to pri-miR-
7, decreased in vitro processing of pri-miR-16. 
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Whilst the mechanisms described here were studied in specific cellular contexts, it is 
not known whether they operate in other scenarios, and it is of interest to 
understand the extent of their involvement in miRNA regulation. For example, 
HADHB is a metabolic enzyme that is ubiquitously expressed in cells and it would be 
interesting to know the context required for its involvement in miRNA regulation. 
Similarly, CIRBP is a stress response protein that is upregulated in response to various 
stimuli and that could have a role in remodelling the expression patterns of miRNAs 
in response to stress, including miRNAs outside of the 14q32 cluster.  
On the other hand, levels of miRNAs in the 14q32 cluster are regulated in response 
to many cellular and extracellular conditions other than ischemia and therefore it is 
likely that other protein factors will be involved in their regulation. This is illustrated 
by the number of proteins identified to bind to pre-miR-329 and pre-miR-495 through 
RP-SMS, but also through regulation of the cluster by Lin28a during neurogenesis. 
Lin28a was shown to upregulate various members of the cluster and specifically was 
shown to bind miR-541. However, knockdown of Lin28a was not sufficient to reduce 
the levels of miR-541, once again showing that an individual miRNA is likely to be 
subject to various forms of regulation simultaneously. 
The regulation of miRNA biogenesis by RBPs is also dependent on the cellular 
environment, as seen by studying the effects of oleic acid on these interactions. 
Whilst in this study the focus was around the displacement of regulatory complexes 
from the miR-7 CTL, it was also shown that oleic acid has an effect on other protein 
complexes, and the full regulatory potential of oleic acid is unknown.  
160 
 
Regulation of miRNA biogenesis by individual protein factors is always context 
specific, with all these factors interacting in complex regulatory networks to fine-tune 
the levels of miRNAs, and by increasing our understanding of the details involved in 
miRNA-protein interactions we can better understand the larger regulatory networks 
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